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PREFACE 
INTRODUCTION TO DISSERTATION 
Mechanisms responsible for junctional SR subdomain formation from ER have 
remained undefined.  This lack of understanding hampers our ability to understand 
changes in SR function in disease; such as the dramatic changes in CSQ2 structure 
that we validated through a series of measurements made on control and failed heart 
samples.  In this research, we developed a new model of the early cardiac secretory 
pathway.  By defining the individual steps of trafficking for CSQ2 and for its 
transmembrane binding partners TRD and JCT, we will be able to develop new 
hypotheses regarding cellular mechanisms of change. 
This Dissertation research involves two studies directed at the junctional 
sarcoplasmic reticulum (SR) and aspects of its dynamic cell biology.  In Chapter 3, we 
describe our investigations of CSQ2 purified from control and failed heart tissue.  Mass 
spectrometric measurements of the intact CSQ2 pool provide detailed data regarding 
glycosylation and phosphorylation states in vivo.  We conclude that the observed 
changes in cardiomyopathies represent alterations in intracellular trafficking within the 
ER of cardiomyocytes.  Chapter 4 and 5 describe a series of studies in which we 
determined the trafficking pathways of newly made junctional SR proteins as a way to 
better understand the mechanisms underlying changes in protein modification.  The 
studies described in this Dissertation, we believe, provide important new insights into 
the mechanisms of long-term change in cardiomyocytes that might underlie changes 
reported in diseased heart.  
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CHAPTER 1 
BACKGROUND 
1.1 Cardiomyocytes  
1.1.1 Cardiomyocytes in the intact heart 
Cardiomyocytes are specialized cells used to generate force in response to 
depolarization of the heart.  These cells are large (100-150 m long, 20-35 m wide), 
binucleated, and surrounded by a plasma membrane known as the sarcolemma. 
Invaginations of the sarcolemma at regular intervals form transverse tubules (T-
tubules), which have roughly a 200 nm diameter. [1, 2].  The T-tubules are not strictly 
transverse and can also communicate longitudinally, across several sarcomeres [3].  
Intercalated disks spanned by gap junctions join adjacent cells and allow for rapid 
conduction of action potentials; hence, all cardiomyocytes contract in synchrony.  The 
fundamental contractile unit in striated muscle is the sarcomere, defined as the region 
confined between two Z-lines.  Chains of contractile units comprise myofibrils, and 
these contain the contractile thick (myosin), thin filaments (actin and others), and titin 
[4].  Contractile force is generated by interaction of actin and myosin, and regulated by 
Ca2+ release from intracellular membrane stores.  
1.1.2 Isolated and cultured cardiomyocytes 
To explore myocardial cell biology, primary cardiomyocytes can be isolated and 
cultured.  Although neonatal cells are more stable, adult cardiomyocytes are preferred 
for cell biological studies because the adult phenotype represents such a unique cell 
system [5].  The technique for isolating viable adult ventricular myocytes was first 
described in 1976 [6] and adult cells were first cultured in 1977 [7].  Several advantages 
to culturing adult primary cardiomyocytes include: ability to carry out longer-term studies 
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that allow manipulation of protein expression [8], examination of a single cardiomyocyte 
in a controlled environment, and visualization of their structural components by a series 
of well-characterized protein markers.  Hence, utilization of cultured adult 
cardiomyocytes allows for the extrapolation of results to the in vivo myocardium and 
thus, complements intact heart preparations or whole animal studies.  
1.2 Cardiac sarcoplasmic reticulum  
A network of interconnecting intracellular membranes, the sarcoplasmic reticulum 
(SR), is largely equivalent to the endoplasmic reticulum (ER) found in other cell types.  
Besides its canonical universal role as the biosynthetic and secretory pathway, 
subcompartments of cardiomyocyte ER may surround each myofibril, taking on a similar 
pattern in each of the hundreds of sarcomeres in the cell (Figure 1-1).  It is this 
extensive and unique sarcomeric component of the cardiomyocyte ER that gives rise to 
its unique reference as SR.  SR is known to play an important role dedicated to storage 
and release of Ca2+ for regulating muscle contraction and excitation-contraction 
coupling.  SR is comprised of two distinct functional subdomains, each associated with 
one of its two major functions: Ca2+ reuptake and Ca2+ release.  The site of Ca2+ 
reuptake remains less well defined morphologically.  The primary protein activities 
associated with these two functions are the SR/ER Ca2+-ATPase (SERCA) and 
ryanodine receptor (RyR), but freeze-etch studies suggest that abundant SERCA is 
found across sarcomeric membrane structures, including in bilayers close to SR-
sarcolemma junctions [9].  RyR are a second major protein complex, and these have 
almost exclusively been described extending as “feet” across the SR-sarcolemma 
junctions.  The Ca2+ -release complex has been studied using multiple biochemical, 
biophysical, and microscopic techniques, 
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Since the proteins associated with these two major activities are relatively well 
characterized (discussed below), antibodies to these various proteins serve as 
important markers for the two subdomains, which has permitted many investigations of 
their respective localizations.  The vast majority of studies to date have focused on the 
Ca2+ release subdomain, and its subcellular morphology.  It is clear from many studies 
that Ca2+ release occurs from a specialized area of the SR that abuts the T-tubules, and 
these sites appear by immunofluorescence as a series of puncta that overlie the Z-disks 
of the myofilaments (Figure 1-1).  
Figure 1-1. Depiction of T-tubules, 
sarcoplasmic reticulum (SR) and 
myofilaments in a mammalian cardiac 
muscle cell. Each myofibril is 
surrounded by an intermembrane 
network of free SR (blue arrow) and 
junctional SR cisternae (red arrow 
head) that forms close to T-tubules 
(green double head arrow), which 
invaginate the cardiomyocyte near Z-
lines (Z).  
1.2.1 Morphological characterization 
Studies using thin section electron microscopy describe the cardiac intracellular 
membrane morphology.  Throughout ventricular myocytes, the SR consists of 
structurally diverse junctional, corbular and network (also referred to by many as 
longitudinal or free) SR.  Spanning the region between the T-tubules, a series of 
interconnected tubules form the network SR.  Specialized junctions of network SR with 
sarcolemmal T-tubules form the junctional SR, resulting in close juxtaposition (~15 nm) 
of RyR and L-type Ca2+ channels where Ca2+ is released to initiate muscle 
contraction[10-12].  
A protrusion of the SR network that does not form junctions with the sarcolemma, 
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but expresses RyR, is corbular SR [13, 14].  Corbular SR and non-junctional SR 
(prevalent in atria), are not generally thought to be involved in depolarization-induced 
Ca2+ release.  Non-junctional SR is also the primary source of Ca2+ release in birds [3].  
The two major functions of cardiac SR that are typically discussed, Ca2+ release and 
Ca2+ reuptake, are therefore not necessarily synonymous with the two 
subcompartments of junctional and free SR.  The various terminologies reported to date 
are descriptive of the overall sarcomeric morphology, but more detailed morphological 
descriptions may not be warranted until a better understanding of the relationship 
between SR and the biosynthetic/secretory pathway can be established.  Even less 
clear is how junctional SR and free SR subcompartments are maintained as dynamic 
subcompartments of the cardiomyocyte secretory pathway.  
1.2.2 SR and ER markers 
The ER is a multifunctional organelle in all cells, and the vast majority of proteins 
are ubiquitously present in all cell types.  In cell types other than muscle, ER is probably 
considered more for its roles in protein biosynthesis and secretion.  Among the more 
abundant proteins found in all cells are a group of luminal resident proteins that can be 
generally referred to as "reticuloplasmins” [15, 16].  Whereas luminal proteins should be 
secreted through bulk flow, the reticuloplasmins are actually retained in the ER.  Over 
time, it has became understood that most, if not all, of these reticuloplasmins are 
involved in the folding of other proteins inside the secretory pathway.  This function has 
become generally known as "chaperone" activity.  The prototypical member of the 
family is GRP78 (glucose-regulated protein, MW 78 kDa), also commonly known as the 
protein BiP (Binding-immunoglobulin protein), named for its role in assisting folding of 
antibody molecules in the B-cell ER [17].  GRP78 may have a wide role in folding 
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nascent polypeptides as they are translated, serving as a template upon which proteins 
fold in conjunction with the aqueous environment of the ER lumen.  With the cloning of 
several of these ER resident proteins, it was discovered that a common C-terminus 
tetrapeptide (-KDEL) was responsible for its ER retention, and a KDEL receptor(s) is 
now well characterized that retrieves these chaperones back to ER [18].  These findings 
helped lead to the understanding of basic cell biology, as it was discovered that a 
retrograde trafficking pathway was present in all cells (see Section 1.4.1). 
Myocyte ER/SR contains both the common ER reticuloplasmins (Cala and Jones 
1994) along with similar myocyte specific proteins, calsequestrin (CSQ), sarcaluminin, 
and histidine-enriched Ca2+-binding protein [16]. CSQ alone is enriched and localized to 
the junctional SR subcompartment.  None of the myocyte enriched luminal ER/SR 
proteins, however, contain the KDEL retrieval sequence, and so the mechanisms for 
their ER/SR enrichment have not been understood.  In the case of CSQ, data suggests 
that it is retained in particular subcompartments due to its unique and subcompartment-
dependent Ca2+-dependent polymerization [19].  Comparable mechanisms may be 
responsible for the concentration of sarcaluminin and histidine-enriched Ca2+-binding 
protein in free SR.  Because of the abundance of the reticuloplasmins in the ER and 
SR, they are often used as protein markers of ER and SR.   
The locations within the cardiac ER in which protein biosynthesis occurs, and 
areas from which SR proteins are trafficked to ER subdomains (e.g. free versus 
junctional SR) have remained largely undefined.  Studies have shown that diffusion of 
Ca2+ occurs between ER and SR compartments suggesting that as a Ca2+-handling 
system, there exists a breadth of functional domains across the biosynthetic/secretory 
pathway [20]. 
6 
	
1.3 Proteins involved in Ca2+ homeostasis  
1.3.1 Ca2+ homeostasis in the cardiomyocyte 
Rises in the levels of intracellular Ca2+ in the cytoplasm ([Ca2+] in) during systole 
are highly regulated, and regulation of Ca2+ cycling is fundamental for achieving 
maximal contraction.  When plasmalemma and T-tubules are depolarized, a Ca2+ 
current flows through the L-type Ca2+ channels.  The Ca2+ that enters the cell through 
the L-type Ca2+ channels (trigger Ca2+) as a result of depolarization, binds to the RyR, 
and triggers the release of a larger flux of Ca2+ (activator Ca2+) from the SR into the 
cytoplasm.  This process is termed Ca2+ -induced Ca2+ release [4, 21] (Figure1-2).  The 
magnitude of Ca2+ release depends on the rate of filling of the SR with Ca2+, the time 
interval between successive release events, and the magnitude of the trigger Ca2+ [22].  
The rise and fall of Ca2+ that precedes every contraction is known as the Ca2+ transient.  
Figure 1-2. Schematic diagram of junctional SR 
with T-tubule and the Ca2+-induced Ca2+ 
release process. The protein transmembrane 
components of junctional SR: triadin (TRD), 
junctin (JCT) and luminal calsequestrin (CSQ) 
bound to Ca2+ (red spheres) associated with 
the Ca2+ -release channel (ryanodine receptor, 
RyR2). Upon depolarization Ca2+ enters 
through the L-type Ca2+ channel, triggers the 
release Ca2+ from the SR through RyR, a 
process known as Ca2+ induced Ca2+ release, 
leading to contraction. During relaxation, 
SR/ER Ca2+ ATPase (SERCA) reuptakes Ca2+ to restore the Ca2+ levels in SR 
(Modified from [26]. 
Ca2+ transients lead to Ca2+ binding to troponin C (Km~0.1 μM) [23] inducing 
subsequent conformational changes to activate actinomyosin ATPase, which result in 
development of force.  With activation of striated muscles, the troponin-tropomyosin 
complex on the thin actin filaments transduces chemical energy into mechanical force 
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[24] and exposes myosin binding sites, thus, allowing formation of cross bridges, 
conversion of ATP chemical energy into force, sliding of the filaments, and shortening of 
the sarcomeres [25].  
The released Ca2+ is removed from the myofilaments and cytosol, into the SR 
lumen by SERCA, into the extracellular space by plasma membrane Na+,Ca2+-
exchanger and plasma membrane Ca2+-ATPase, or into the mitochondria via a Ca2+ 
uniporter.  Over the course of many depolarizations, in order for the cell to remain in a 
steady state with respect to cellular Ca2+ balance, the efflux and influx of Ca2+ must 
remain equal [4]. 
1.3.2 Major proteins of the Ca2+ -release complex  
A quaternary complex of four proteins: RyR, triadin (TRD), junctin (JCT) and 
CSQ, is thought to be primarily involved in the coordinated operation of Ca2+ release, 
which has been proposed based on immunoprecipitation and fusion-protein pull down 
assays [27].  Physical coupling of CSQ, TRD and JCT modify the resting and voltage-
activated Ca2+ release through RyR, based on junctional SR Ca2+ load, suggesting that 
these proteins play an active role in relaying information to RyR about the Ca2+ load in 
the SR [28].  Other studies, including studies of TRD and JCT knockout mice, have 
suggested that these proteins may play a more structural role.  The known problem with 
studies of transgenic and knockout mice has been the coordinated changes in other 
junctional SR proteins (section 1.6.1) 
RyRs mediate the release of Ca2+ from the SR, which is an essential step in 
cardiac muscle contraction [29].  The RyR is a homotetramer, with a predicted size of 
564 kDa in humans, encoded in mammals by three genes with strong sequence 
homology between the isoforms: RYR1 (first to be sequenced and cloned in 1989) [30] 
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is expressed in skeletal muscle, RYR2 in cardiac muscle [31], and RYR3 in smooth 
muscle and the brain [32].  Between the T-tubule and terminal cisterna membrane, the 
cytoplasmic domain of RyR2 forms a major part of the junctional complex [33].  
In cardiac muscle, mutations in the RYR2 gene are associated with the dominant 
genetic form of catecholaminergic polymorphic ventricular tachycardia (CPVT), a 
familial arrythmogenic disease that manifests in childhood and adolescence [34] and is 
characterized by syncope and sudden death following exercise and emotional stress. 
RYR2 mutations result in “leaky” RyR2 channels by yet unknown mechanisms.  The 
inappropriate Ca2+ release results in increased Na2+, Ca2+ exchanger activity, which 
depolarizes the cell membrane, giving rise to delayed after depolarizations [35].  
Mutations in the RYR2 gene are also associated with stress-induced polymorphic 
ventricular tachycardia and arrhythmogenic right ventricular dysplasia [36].  
1.4 Protein: biosynthesis and trafficking  
1.4.1 Protein synthesis and nascent polypeptide folding  
Protein translation from mRNA is carried out on ribosomes. Large (60S) and 
small (40S) ribosomal subunits assemble at the AUG codon of mRNAs at the 5’-end 
and disassemble at the UAG/UGA/UAA stop codons at the 3’-end.  Cytosolic, nuclear 
and peroxisomal proteins are synthesized on cytosolic ribosomes [37].  However, during 
translation, short hydrophobic peptide signal sequences direct a subset of nascent 
polypeptides to assemble on ribosomes that are bound to the ER.  Proteins translated 
on rough ER include those destined for the secretory and endocytic compartments (ER, 
Golgi, endosomes and lysosomes), for the plasma membrane and for secretion to the 
extracellular space.  The signal sequences for these cellular proteins bind the signal 
recognition particle in the cytoplasm, thus slowing down chain elongation [38, 39] until 
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the ribosome engages a proteinacous channel, the translocon, formed by two Sec61αβγ 
heterotrimeric complexes at the ER membrane [40, 41].  With the formation of a 
translocon, the protein synthesis is resumed, the short hydrophobic signal sequence 
may then be removed (for some proteins such as CSQ2), and nascent chains co-
translationally enter the ER lumen [42].  
1.4.2 Co-translational asparagine (N)-linked glycosylation 
The most prominent modification of secretory proteins is N-linked glycosylation, 
which occurs for a very high percentage of membrane and secreted proteins [43].  
Oligosaccharyl transferase (OST) transfers preassembled glycans, composed of three 
glucoses, nine mannoses, and two N-acetyl glucosamine residues (GlcNAc2Man9Glc3), 
from a lipid pyrophosphate donor in the ER membrane, dolichol-PP, to a nascent 
polypeptide chain [44].  The transfer to the consensus sequence Asn-X-Ser/Thr 
generally occurs co-translationally, once it has emerged 12-14 amino acids (30-40 Å), 
aligning the Asn with the active site of OST in the ER lumen [45].  An inhibitor of N-
linked glycosylation, tunicamycin, leads to improper or incomplete folding, and failure to 
reach native conformation for proteins that do not pass ER quality control [46].  These 
proteins are retained in the ER [47], and eventually degraded [48], a process termed ER 
associated degradation.  A mature properly folded protein contains the glycan 
GlcNAc2Man9, but this glycan will be reliably and predictably trimmed and modified as it 
traverses the secretory pathway. 
1.4.3 Post-translational modification of the (N)-linked glycans 
Early quality control mechanisms are involved in the trimming of glucose from ER 
glycoproteins.  The enzyme glucosidase I removes the first glucose of the glycan core, 
followed by the removal of the second glucose by glucosidase II.  Molecular chaperones 
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known also as mammalian lectins (such as calnexin and calreticulin, discussed Section 
1.4.1) can bind to the monoglucosylated core of the glycoprotein, exposing it to a thiol-
disulfide oxidoreductase, ERp57, for proper disulfide bond formation during the on going 
folding process.  Glucosidase II removes the remaining glucose residues to release the 
bound chains from calnexin and calreticulin.  Incompletely folded proteins get 
reglucosylated by UDP-Glc: glycoprotein glucosyltransferase, which serves as a folding 
sensor until the glycoprotein is properly folded or degraded [49]. 
Removal of mannose residues occurs first by ER α1,2-mannosidase I [50, 51], a 
class I mannosidase [52], which catalyzes the first mannose trimming step concurrently 
or immediately following glucose trimming. ER α1,2-mannosidase I yield a specific 
Man8GlcNAc2 isomer from Man9GlcNAc2, by cleaving a single α1,2-mannose residue.  
The enzyme is inhibited by kifunesine and 1-deoxymannojirimycin [52].  In rat 
hepatocytes and several other mammalian cell lines, an additional mannosidase 
resistant to kifunesine, termed ER α1,2-mannosidase II, has been identified and shown 
to produce a Man8GlcNAc2 isomer, distinct from that of ER α1,2-mannosidase I [51, 
53].  
It is known that CSQ2 undergoes extensive mannose trimming from Glc2Man9 
(Man9) down to Man3-4 [54, 55].  However, these authors have argued that post-ER 
glycan trimming of CSQ2 would be expected to add terminal GlcNAc to the CSQ2 
protein (Figure 1-3).  The fact that CSQ2 molecules do not contain any additional 
sugars, but instead only undergoes mannose trimming is consistent with the idea that 
CSQ2 molecules never leave the ER, and that only ER α-1,2 mannosidase is expected 
to act upon CSQ2.  Characterization of mannosidases in individual cell types has not 
been carried out, and little data exist on the distribution of mannosidases in myocytes, 
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and so the connections between CSQ2 glycan structure and its intracellular trafficking 
remain uncertain. 
 
Figure 1-3. N-linked glycan biosynthesis and CSQ2 glycan trimming along the secretory 
pathway. From right to left: glycan synthesis begins at the cytoplasmic side of the ER 
membrane and is then flipped to the luminal side of the membrane. Once the formation 
of the core oligosaccharide (Glc3Man9GlcNAc2) is complete, the enzyme OST (not 
shown) catalyzes the glycosylation of the Asn residue in the nascent growing peptide. 
When the glycoprotein has properly folded (grey oval) the process of mannose trimming 
occurs by intracellular mannosidases as the protein traffics through the ER and Golgi. 
The glycan of CSQ2 is highly mannose trimmed contains only a variable number of 
terminal Man residues, and no additional sugars are added, indicating that it does not 
reach the Golgi, but is retained within junctional SR to perform its physiological function. 
(Modified from [43] 
1.4.4 Rough ER and smooth ER  
The ER is a membrane protein biosynthesis and maturation compartment 
topologically equivalent to the extracellular milieu [56].  It is classically subdivided into 
rough ER areas that are sheet-like and ribosome studded and smooth ER that is more 
tubular in structure.  ER domains are continuous, forming an intricate network 
continuously undergoing rearrangements, composed of fenestrated cisternae and 
anastomosing tubules through most of the cytoplasm [57].  
Rough ER a highly dynamic part of the ER organelle marked by the site of 
protein assembly and includes the translocon, a large complex of proteins that make up 
the entry point into the secretory pathway.  As discussed above (section 1.2.2), high 
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concentrations of molecular chaperones in the ER are thought to assist protein 
maturation and prevent unfolded chain aggregation.  Rough ER contains homologs of 
classical chaperone members of the Hsp70 and Hsp90 family, namely GRP78/BiP [58] 
and GRP94 [59].  There are many other chaperones including lectin-like molecular 
chaperones, such as calnexin, calreticulin and calmegin [60], which recognize the core 
oligosaccharide on nascent proteins, and further assist in proper folding of ER 
glycoproteins.  Resident ER luminal proteins discussed above, such as GRP78/BiP, 
GRP94 and protein disulfide isomerase, which covalently modifies newly synthesized 
proteins, share a common carboxyl-terminal tetrapeptide sequence, the KDEL motif, 
which is necessary for retention of luminal ER proteins and sufficient to cause a 
normally secreted protein to be retained [61].  Retrograde transport of KDEL containing 
proteins, from the intermediate compartment and the cis Golgi, is mediated by a 
membrane-bound KDEL receptor [62].  
1.4.5 ER exit sites and the intermediate compartment 
A great deal of research over the past 10-20 years has established a basic 
mechanism by which folded proteins exit the ER to continue across more distal 
compartments of the secretory pathway.  Transitional ER or ER exit sites form at small 
ribosome free regions within the rough ER from which cytosolic coat protein II (COPII) 
vesicles arise [63, 64].  COPII vesicles package properly folded and assembled proteins 
and transport them out of the ER into the Golgi-directed pathways.  A COPII coated bud 
that transport cargo anterogradely, is initially formed by Sar1p recruited to the ER 
membrane followed by Sec23-Sec24p and finally Sec12-Sec31p [65].  These early 
proteins of the ER exit apparatus, which are recruited to ER exit sites, are often used as 
markers.  Sec23 has been used as a marker for ER exit sites in cultured 
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cardiomyocytes [66]. In the adult cardiomyocyte, it remains to be established where ER 
exit sites are found, and whether SR formation from ER might require ER exit. 
These COPII transport vesicles fuse to generate an ER-Golgi intermediate 
compartment (ERGIC) in mammalian cells.  While the ERGIC may consist of discrete 
intracellular structures, it has little functional interest, other than its role as a step that is 
both post-ER and pre-Golgi.  Once in Golgi, proteins are transported between 
compartments via COPI coated vesicles [67].  
1.4.6 Golgi  
COPII vesicles exit the ER to transfer lipid and membrane protein to cis Golgi 
cisternae. An important and established activity of the Golgi is the modification of glycan 
moieties, which also serves as a marker of the transfer of a glycoprotein from the ER to 
the Golgi and beyond.  Numerous studies over time have focused on the processing of 
N-linked glycoproteins continues in the Golgi.  In addition, glycan modifying enzymes 
such as glycosyltransferases, glycosidases, and nucleotide sugar transporters are 
present in a defined manner within Golgi compartments such that each acts 
consecutively on specific substrate(s) generated earlier in the pathway.  
GlcNAc moieties are commonly added to free hydroxyl termini of N-linked 
glycans by the enzyme GlcNAc transferase.  While this modification is likely to involve 
widespread changes in the functions of individual glycoproteins, its determination in 
individual proteins is often used by scientists to establish basic trafficking steps.  
Terminal GlcNAc moieties are thought to promote resistance to the enzyme 
endoglycosidase H, compared to high mannose oligosaccharides added in the ER.  
Cisternal migration moves proteins destined to be secreted to the trans face of the Golgi 
and subsequently into a complex network of vesicles, termed trans Golgi network 
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(TGN).  The TGN contains multiple sorting domains and produces clathrin-coated 
vesicles, but not COPI vesicles, whereas earlier Golgi cisternae produce COPI vesicles.  
In addition to serving as the exit face of the Golgi, the TGN is the interface between the 
Golgi and the endocytic system.  Clathrin cooperates with adaptors to produce vesicles 
that carry certain cargoes from the TGN to endosomes [68].  Secretory cargoes are 
delivered from the TGN to the plasma membrane by a variety of routes.  Therefore, 
although protein N-linked glycosylation and other post-translational modifications in the 
various organelles are of fundamental importance in protein function in the cell, the 
experience gained has established glycoproteins as reliable measures of protein 
trafficking 
1.4.7 Protein trafficking through the cardiac secretory pathway 
For proteins to exert their functions, proper subcellular localization is essential. 
Human diseases have been linked to aberrant localization of proteins caused by 
dysregulation of protein trafficking [69].  Basic anterograde flow through the secretory 
pathway involves proteins within membrane vesicles moving along default cytoskeletal 
pathways, either to be secreted (the case for luminal proteins) or to plasma membrane 
(for transmembrane proteins).  
Yet, the intracellular membrane trafficking pathways and targeting mechanisms 
involved in the final localization of junctional SR proteins remain unknown.  One reason 
for this is the fact that cardiomyocytes are not the subject of wide study of cell biologists 
due to their unique structure.  Meanwhile, cardiac SR biologists have not investigated 
protein trafficking due in large part to the enormous effort and expertise of laboratories 
in studying the details of the Ca2+ release event, at the cost of ignoring the longer-term 
changes that would occur with changes in cell biology.  Given that cardiac pathologies, 
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and loss of contractile strength in the myocardium, are likely to involve more chronic 
cellular changes, these deficits in understanding form critical needs for research.   
1.5 Junctional sarcoplasmic reticulum proteins  
1.5.1 Calsequestrin  
CSQ is an abundant myocyte protein, and major Ca2+-binding protein in the SR 
lumen of cardiac and skeletal muscle.  The fast-twitch skeletal muscle isoform (CSQ1) 
was first discovered in 1971 [70, 71] and is encoded by CASQ1 gene [72].  The protein 
in heart, encoded by CASQ2 gene [73], was not discovered until 1983.  The two 
sequences exhibit 65% identity (Figure 1-4), and both are highly acidic proteins 
(isoelectric point, pI ~ 4), due to more than 37% Asp and Glu residues in the sequence.  
Figure 1-4. Human CSQ amino acid sequences. Sequences of human cardiac (black) 
and skeletal (red) muscle CSQ isoforms are 65% identical. The site of N-linked 
glycosylation (purple shaded box) is conserved in both isoforms. A specific cardiac 
isoform tail (cyan shaded box) contains two CK2-sensitive serine (S) phosphorylation 
sites in humans (NCBI database). CSQ1, like CSQ2, undergoes glycosylation on 
316Asn. Because it does not contain the unique C-terminus of CSQ2, it is not 
phosphorylated in vivo.  It can be phosphorylated in vitro by protein kinase CK2 on 
Thr373, a site that is not phosphorylated in vivo [74].   
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CSQ1 was originally discovered as a Ca2+ -binding protein component of muscle 
microsomes, localized to the lumen of the skeletal muscle SR membrane.  The mass of 
the protein is similar for CSQ1 and CSQ2, having an approximate molecular weight of 
42,000 Da.  Both CSQ1 and CSQ2 migrate aberrantly on SDS-gels (Laemmli reagents), 
with CSQ1 migrating as if a 63 kDa protein, while CSQ2 runs at 55 kDa.  These 
aberrant mobilities, related to the low SDS-binding of the protein, contributed to the idea 
prior to 1983 that CSQ did not exist in the heart. When CSQ1 and CSQ2 are compared 
form the same species, CSQ1 is always slightly smaller than CSQ2 because it lacks a 
20-25 amino acid C-terminus.  CSQ1 is exclusively found in fast-twitch (type II) muscle 
fibers, while CSQ2 exists in slow-twitch fibers [75].  
The three dimensional structure of CSQ was first reported by Wang et al 
(Figure1-5), showing that the monomeric form of CSQ is made of three domains; I 
(residues 12-124), II (residues 125-228) and III (residues 229-352), which are nearly 
highly similar to the functional topology of bacterial thioredoxin, however, CSQ has not 
been shown to exhibit thioredoxin activity itself.  Each CSQ domain consists of four α-
helices that line (two on each side) a hydrophobic core, consisting of five β-sheets.  The 
domains are connected by short sequences, which along with the secondary structural 
elements (α-helices), consist of acidic residues that mark the overall protein as 
hydrophilic [76].  
Kang and co-workers [77] have also compared the surface charge densities for 
CSQ1 and CSQ2 and shown clear differences that may account for differences in their 
polymerization characteristics (section 1.5.1.1.1).  These differences, however, cannot 
be immediately translated into differences in their biochemistry and biology because 
CSQ-interaction proteins (for example, TRD and RyR) are also generally tissue specific, 
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as is the structure of the sarcomeric SR compartments.  
Figure 1-5. Ribbon diagram of CSQ 
structure. Monomeric CSQ2 
consists  
of three domains, with the 
phosphate molecules (red triangle) 
schematically attached to serine 
residues 378, 382 and 386 in the 
(canine) cardiac-specific tail (red 
rectangle). The glycan is also 
schematized: 9 mannoses (blue 
circles) and 2 GlcNAc (purple 
squares) is attached to Asn316 
(Modified from [76]). 
1.5.1.1 Cardiac muscle calsequestrin (CSQ2) 
CSQ2 is a major protein constituent of junctional SR in hearts that functions in 
Ca2+ release through its effects on the RyR2 via the two transmembrane proteins TRD 
and JCT [78-80].  In spite of decades of research, the functional role of CSQ2 in the 
heart remains unknown.  It was long thought to act as a Ca2+ buffer based upon its 
ability to bind very large amounts of Ca2+ in vitro (30-50 mol Ca2+/mol CSQ), however, 
studies of CSQ2 depletion in mice showed that levels of SR-releasable Ca2+ were not 
altered.  Studies described in this dissertation are not meant to determine the function of 
CSQ2, however, elucidation of novel functions of its cell biology, in combination with an 
examination of its changes in structure in animals with heart failure, offer interesting 
new insights into its possible role in maintaining structural features of the 
cardiomyocyte. 
1.5.1.1.1 Ca2+ binding and polymerization  
CSQ2 undertakes major changes in structure upon Ca2+ binding, and converts 
from a “sticky” conformation, which binds stably to phenylagarose in micromolar Ca2+, to 
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a hydrophilic conformation in millimolar Ca2+, which causes it to immediately unlatch 
from phenylagarose (Cala and Jones, 1983).  This Ca2+-dependent conformational 
change is widely used to purify CSQ2 from crude extracts (Cala and Jones, 1983; 
Jacob et al, 2012).  Cloning of CASQ revealed that the encoded protein does not 
contain a distinct Ca2+ binding domain as part of its secondary structure.  From the 
crystal structure, it was determined that Ca2+ binds to CSQ2 through electrostatic 
attractions to negatively charged residues that are, exposed on the surfaces.  At low 
Ca2+ concentration CSQ2 is present as a soluble monomer.  As the Ca2+ concentration 
increases, front-to-front surface interactions occur, followed by back-to-back surface 
interactions (Figure 1-6) as more Ca2+ is required to shield the negatively charged 
residues present at the C-terminus [77].  
The segregation of CSQ2 to junctional SR has been hypothetically accounted for 
by TRD and JCT transmembrane proteins restricted to junctional SR [27, 81-83].  
However, overexpression studies of CSQ in non-muscle cells show clearly that 
polymerization can determine localization [19, 84].  CSQ2 is very efficiently retained 
within the ER lumen of all non-muscle cells examined to date.  Its strict localization is 
confirmed by its glycan structure, which contains only Man9 and Man8 glycans. 
Insertion of epitope-tags was found to reduce ER retention compared to wild-type 
CSQ2, suggesting that these disrupted forms have undergone a loss of the sequence-
specific polymerization that is necessary for proper localization [84].  Finally, CSQ1 
does not concentrate in the ER of non-muscle cells, instead CSQ1 efficiently 
polymerizes along microtubules (MTs) that emanate from the microtubule-organizing 
center. CSQ1 glycans undergo a more substantial mannose trimming (Man 5-9).  Thus, 
CSQ2 and CSQ1 each polymerize, but they concentrate in either ER or ERGIC, 
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respectively [19]. It is hypothesized that in normal heart, CSQ2 is also retained in 
junctional SR by this subcompartment-specific polymerization [85]. 
Figure 1-6. CSQ polymerization 
model. A representation of face-to-
face (through N-terminal arm) 
interactions of CSQ monomers, 
followed by back-to-back interactions 
(through C-terminal tail), as Ca2+ 
concentration increases. CSQ 
eventually forms a linear polymer with 
the front-to-front and back-to-back 
interactions (Modified from [86] 
1.5.1.1.2 N-linked glycosylation  
N-linked glycosylation (section 1.4.2) of CSQ2 and CSQ1 occurs on Asn316 
(Figure1-3 and 1-4), which is a conserved residue among species and glycoforms [87].  
In non-muscle cells, CSQ2 exists in two glycoforms (Man8- and Man9-GlcNAc2); 
however, CSQ2 purified from tissue (native) exists in a larger range of glycoforms 
(Man1-4GlcNAc2), exhibiting a high degree of mannose trimming compared to most 
proteins [49, 54], suggesting that CSQ2 remains inside the classical mammalian ER 
compartments, where mannosidases are thought to be involved in glycan trimming 
(section 1.4.3).  It is therefore expected that CSQ2 does not traffic to early Golgi 
compartments, because GlcNAc residues would otherwise be expected to be present 
on CSQ2 glycans. 
The discovery that CSQ2 glycan structure is reproducibly altered in heart tissue 
from beagles induced into failure by tachypacing [55] suggested that CSQ2 trafficking 
was altered.  The CSQ2 glycan present in failed hearts are comprised of two general 
structures: those with relatively standard, highly trimmed structures (Man4-7), and a 
new population of molecules not present in normal dog heart tissue.  These new glycan 
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structures show a lack of mannose trimming (Man9,8) expected for newly made 
proteins in the ER (discussed in Chapter 3). 
1.5.1.1.3 Phosphorylation by protein kinase CK2 
The carboxyl terminus of canine CSQ2 molecules extends an additional 20-25 
amino acids from the corresponding CSQ1 sequence (Figure 1-4).  This cardiac-specific 
tail is highly phosphorylated in vivo by protein kinase CK2 (formerly casein kinase II), on 
a cluster of three serine residues (Ser 378,382,386) in the canine form of CSQ2, but two 
serine residues in other species (Table 1-1) [66, 74].  Consisting of two tightly 
connected β subunits and two α/α’ subunits, protein kinase CK2 is present in all 
eukaryotic cells [88].  
The presence of phosphate on purified CSQ2 has been shown by multiple 
experimental approaches [54, 74], but the clearest indication is the presence of mass 
isoforms that differ only in phosphate content.  Following removal of the CSQ2 glycan 
from purified CSQ2 using endoglycosidase H, mass spectrometry of intact CSQ2 
protein from heart tissue is composed of only four mass peaks, corresponding to 0, 1, 2, 
or 3 phosphates, each differing by about 81 Da.  The stoichiometry of canine CSQ2 
phosphorylation is ~1.5 mol Pi/mol CSQ, but the phosphates are not evenly distributed 
among CSQ2 molecules. CSQ2 is thought to undergo constitutive phosphorylation in 
the early secretory pathway compartments and dephosphorylation in distal ones [89].  
Phosphorylation has been hypothesized to occur in the rough ER, due to the fact that 
higher phosphorylation levels were observed in the glycoforms characteristic of proximal 
secretory compartments [89].  
In contrast to more commonly studied hormone-mediated phosphorylation 
reactions, CSQ2 phosphorylation by CK2 has been hypothesized to result from a 
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process that occurs co-translationally.  The data that supports this hypothesis is as 
follows: 1) CK2 acts as the CSQ2 kinase in intact cells, but can theoretically only co-
localize with CSQ2 prior to translocation across the ER during its biosynthesis [66], 2) 
CSQ2 phosphorylation is maximal for CSQ2 molecules with unprocessed glycans, and 
decreases in relation to extent of mannosidase processing [89] and 3) phosphorylation 
in situ is only measurable when CSQ2 is highly expressed under cytomegalovirus 
(CMV) promoter, consistent with the requirement for a co-translational reaction [89].  
This phosphorylation reaction has been validated by another lab [90], but has primarily 
been studied by the Cala laboratory. 
Table 1-1. CK2 sensitive phosphorylation-sites present in the carboxyl-terminal tail of 
CSQ2.  
1.5.1.1.4 Role of CSQ2 in Ca2+ homeostasis   
CSQ2 is the most abundant Ca2+ binding protein in cardiac membrane, although 
several Ca2+-binding proteins such as histidine-rich Ca2+ binding proteins and 
sarcaluminin are also present in high levels in SR lumens [16].  From the time of its 
discovery, CSQ was predicted to act as a Ca2+ buffer and storage protein [91].  Earlier 
acute overexpression studies in cultured adult rat cardiomyocytes have supported this 
hypothesis, since doubling the levels of CSQ2 in cultured cells produced enhanced Ca2+ 
transients [92], and increased SR Ca2+ content (load), determined as 10 mM caffeine 
Sequences from the C-terminal cardiac specific tail are listed, with serine residues 
(S) as the sites phosphorylated by CK2 for different species. For rat & dog. 
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releasable Ca2+.  This was the first study to offer physiological data that the Ca2+ 
released during muscle contraction emanates from CSQ2, as the luminal Ca2+ storage 
protein.  Studies of CSQ2 in bilayer experiments have shown that CSQ2 led to 
increased RyR2 open probability [28, 93].  Such data suggested that, independent of 
any effects on SR Ca2+ buffering, CSQ2 could act directly on RyR2, and that Ca2+ 
release may be regulated by CSQ2.  
1.5.1.1.5 Characteristics of CSQ2-DsRed 
DsRed, a red fluorescent protein cloned from the Discosoma coral [94], is an 
obligate tetramer in vitro [95, 96] and in living cells [96], confirmed by a variety of 
techniques.  A unique subcellular localization of the fluorescent fusion protein CSQ2-
DsRed [19] around the nucleus was observed following its overexpression in cultured 
adult rat cardiomyocytes.  The ability to distinguish the red fluorescent CSQ2 polymer 
from the more mobile monomer was made possible by the immunoreactivity of 
monomers, and loss of immunoreactivity in the CSQ2-DsRed polymer.  The resultant 
pattern showed that the CSQ2-DsRed polymer first accumulates in perinuclear rough 
ER, and is only able to traffic anterogradely as a monomer (Figure 1-7). 
Figure 1-7. CSQ2-DsRed in 
adult cardiomyocytes. When 
CSQ2 is fused to the fluorescent 
protein DsRed it forms 
tetramers that fluoresce red. 
These tetrameric CSQ2-DsRed 
complexes are, interestingly, 
non-immunoreactive with either 
anti-CSQ or anti-DsRed (green).  
(A) Within 20 h overexpression 
of CSQ-DsRed adenovirus, anti-DsRed detects CSQ fusion protein around the nucleus 
that slowly traffics peripherally.  (B) By 48 h in culture, DsRed tetramers are fluorescing 
around the nucleus as protein levels build up. Meanwhile, the monomeric CSQ2-DsRed 
continues trafficking peripherally (Modified from [85].  
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1.5.2 Triadin  
TRD is a transmembrane protein of junctional SR that binds to CSQ and may 
anchor CSQ to the RyR.  It was first identified in 1991 as a 95 kDa integral membrane 
protein enriched in junctional SR vesicles from skeletal muscle, but a smaller, 
alternatively spliced form was reported in heart in 1996 [97].  The majority of the protein 
sequence (C-terminus) is localized in the SR lumen, with a single membrane spanning 
domain and a short N-terminal positively-charged cytoplasmic segment [81, 98] that 
binds on one side of a “KEKE” motif within a beta sheet structure [99].  
The primary isoform expressed in cardiac muscle is triadin-1 (TRD in this 
manuscript), a shorter splice variant of skeletal muscle triadin, arising as an alternative 
splicing from a common gene.  For the first 257 amino acids, triadin in cardiac and 
skeletal muscle are identical.  However, cardiac muscle TRD incorporates a unique 21 
amino acid cardiac specific tail [97, 99]. On SDS-PAGE, canine cardiac TRD appears 
as a doublet, the glycosylated and unglycosylated forms resolving at 40 kDa and 35 
kDa, respectively [99].  Mouse cardiac TRD also occurs in both glycosylated and 
unglycosylated forms [100].  It has been shown in a non-muscle cell model that the 
unglycosylated form of triadin is more rapidly being broken down by the proteasome 
[101].  The glycosylation site (75Asn) is only 7 residues from the ER membrane surface, 
which makes its glycosylation very inefficient.  Why the TRD sequence has maintained 
this inefficient level of glycosylation through its evolution remains an enigmatic feature 
of its structure and cellular processing.  
1.5.3 Junctin  
In 1995, JCT was purified and its primary structure determined; it exhibits 
significant sequence identity to the liver ER aspartyl β-hydroxylase, representing a 
24 
	
unique splice variant present in striated muscle cells. It has limited homology with rabbit 
skeletal muscle TRD, especially in the transmembrane region (type II signal anchor 
domain).  JCT is enriched in junctional SR membranes from skeletal and cardiac 
muscle [102]. JCT consists of 210 amino acids with a molecular mass of 26 kDa; it has 
a short amino acid cytoplasmic N-terminus, a single transmembrane domain and a 
highly charged C-terminal luminal tail that can bind CSQ2 [103].  The protein in heart 
does not from disulphide-linked oligomers and does not appear to be glycosylated [103]. 
1.5.4 Junctional sarcoplasmic reticulum protein-protein interactions 
TRD has been shown to bind CSQ [104], RyR [81] and interact with JCT [27] 
through a common luminal domain.  The binding sites for CSQ [104] and RyR [105] 
contain a KEKE motif localized within residues 210-224.  Since electron microscopy of 
intact muscle shows CSQ adherent to the luminal face of the RyR [106] and TRD has 
the ability to bind both RyR and CSQ, it can be inferred an anchoring function for TRD 
of CSQ.  
Immunofluorescence and immunoblotting show that JCT co-localizes with CSQ 
and RyR [103]. In junctional SR vesicles, JCT has been shown to be the major CSQ 
binding protein in SR [102].  The high levels of basic amino acids were predicted to be 
important for JCT’s ability to bind to CSQ to provide a membrane anchor for CSQ [73].  
The CSQ binding domain on JCT was localized by fusion protein analysis to the 
intraluminal region amino acid residues 46-210, the region containing the charged 
amino acids [27].  In the same study, JCT was shown to interact with CSQ, and the RyR 
in a Ca2+ dependent manner and with TRD in a Ca2+ independent manner.  Other 
studies have more recently suggested that JCT and TRD are not simply redundant, but 
might have distinct properties and detailed functions in the myocyte [83].  
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1.6 Hypertrophy 
When heart muscle get progressively weaker and can no longer pump enough 
blood to meet the metabolic needs of the body, heart failure (HF) can develop from such 
ventricular dysfunction.  Heart failure may also result from one or the sum of many 
causes.  Such a progressive disorder must be managed in regard to not only the state 
of the heart, but to the condition of the circulation, lungs, neuroendocrine system and 
other organs as well.   
Associated with ventricular dysfunction are alterations in cardiac size, shape and 
function.  These changes can result from changes in specific genomic expression, 
molecular mechanisms, or subcellular structures.  Recent studies have observed that T-
tubule integrity is lost in a mouse model of ventricular hypertrophy and HF [107].  The 
reasons for T-tubule reorganization are under active investigation.  One current focus of 
study is the junctional SR protein junctophilin-2, a transmembrane protein that is able to 
interact with phosphoinositides in the T-tubules.  
As a direct activator of myofilaments and thus contraction, Ca2+ is fundamental 
for heart function. In the failing heart, there can exist an inability to properly regulate the 
Ca2+ transient or Ca2+ interaction with contractile proteins.  Changes in the steady-state 
distribution of Ca2+ within the cardiomyocyte of stressed and failing hearts are thought 
to underlie reduced contractility [108-110].  Candidate mechanisms for reduced 
contractility include changes that prevent normal filling of SR Ca2+ stores, normal 
release of Ca2+ [109, 110], and Ca2+-dependent changes in transcription [111-115].  
We recently showed that CSQ2-DsRed protein accumulation at juxtanuclear sites 
could strongly stimulate local spontaneous release of Ca2+ through RyR [116, 117].  
This compartment is also the putative site at which CSQ2 is co-translationally 
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phosphorylated by protein kinase CK2 [66].  Concentration of CSQ2 in this juxtanuclear 
subcompartment might contribute to a functional Ca2+ microdomain that supports a 
cardiac remodelling phenotype [108, 113].  
1.6.1 Cardiomyopathies linked to genetic changes in protein components of the 
Ca2+-release complex in mice  
Mouse models of the protein components of the Ca2+-release complex, while 
validating possible roles of CSQ2 in Ca2+ release, have not been successful in resolving 
molecular mechanisms of Ca2+ release or junctional SR formation.  Beyond the 
complexities that underlie the likely molecular mechanisms, mouse genetic models have 
ended up leading to changes in multiple protein components (Table 1-2).     
Mechanical stress, humoral factors or altered cardiac gene expression lead to 
cardiac hypertrophy, a fundamental adaptation of the adult heart [118].  The central role 
of Ca2+ signaling in cardiac hypertrophy is apparent from studies on transgenic mice in 
which the overexpression of genes encoding for components of this pathway, such as 
the L-type Ca2+ channel, calcineurin and NFAT, TRD, JCT, CSQ2 and Gqα, all result in 
hypertrophy [119].  
Transgenic mice that overexpress CSQ2 have a particularly marked phenotype 
that is characterized by severe cardiac hypertrophy and decreased depolarization-
induced Ca2+ release from the SR. The overexpression of CSQ resulted in a 
compensatory decrease in the expression of its binding partners (JCT, TRD and RyR2) 
within the RyR2 complex [106, 120].  The increase in transcription during hypertrophy 
might result from subtle alterations in the spatio-temporal properties of the individual 
Ca2+ spikes.  Indeed, a broadening of the Ca2+ transient or an increase in its amplitude 
have been recorded in cases in which hypertrophy is induced by modifying the levels of 
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proteins associated with RyR2 [119]. 
Table 1-2. Summary of junctional SR protein overexpression and suppression studies  
Gene 
Symbol Name 
Overexpression 
/Suppression 
Animal 
Model Effect on Other Proteins Implications Ref. 
TRDN Triadin Null Mouse Downregulation of junctophilin-1 and -2 --- [129] 
  Overexpression Mouse Reduced expression of JCT and RyR 
Hypertrophy, 
impaired relaxation 
and reduced 
contractility 
[130] 
  
Co-
overexpression 
of canine TRD 
and canine JCT 
Mouse 
No changes in SERCA2a, 
CSQ, PLB and PMCA 
ATPase levels. RyR 
expression levels 
decreased 28%, however 
the phosphorylation of 
S2809RyR was increased by 
57% 
Mild cardiac 
hypertrophy, 
prolonged 
relaxation, a 
blunted response to 
β-adrenergic 
[131] 
  Null Mouse 
Reduced expression of 
RyR2 (50%), CSQ2 
(~60%), JCT (~92%) and 
junctophilin-1 and -2 
(~40%). No significant 
changes in the non-
junctional SR proteins: 
SERCA2a, PLB 
Loss of Ca2+ 
release units, 
impaired E-C 
coupling, and 
cardiac arrhythmias 
[132] 
JCTN Junctin Overexpression Mouse --- 
Abnormalities in 
muscle contraction, 
narrowing of 
junctional SR, 
compaction of CSQ 
and excess T-
tubule SR 
interactions 
[133] 
  Overexpression Mouse --- 
Increased 
susceptibility to 
atrial fibrillation 
[134] 
  Null Mouse 
No significant changes in 
RyR, phosphorylation of 
S2809RyR, TRD or CSQ, 
histidine-rich Ca2+-binding 
protein, FKBP12.6, SERCA 
or phospholamban levels 
Enhanced cardiac 
function in vivo, 
JCT deficient 
cardiomyocytes 
exhibited increased 
contractile and 
Ca2+ cycling 
parameters 
[135] 
CASQ 
Calseq
-
uestrin 
Murine CSQ 
overexpression Mouse 
No downregulation of RyR, 
TRD or JCT 
Hypertrophy and 
impaired Ca2+ -
induced Ca2+ -
release 
[136] 
  Canine CSQ2 overexpression Mouse 
Reduced expression of 
RyR, TRD and JCT 
Impairment in Ca2+ 
-induced Ca2+ -
release and 
decreased Ca2+ 
spark frequency, 
severe hypertrophy 
and heart failure 
[106, 
137] 
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Ablation of the CASQ2 gene in mice (CASQ-/-) produces a cardiomyocyte 
phenotype in which the SR Ca2+ release is not significantly different from that of wild-
type myocytes.  A 50% increase in total SR volume in these mice could contribute to the 
lack of change in the free Ca2+ concentration.  Another possible explanation would be 
that an increase in other SR Ca2+ binding proteins has occurred in response to the loss 
of the Casq2 gene [121].  Subsequent studies of a heterozygote (CASQ+/-) mouse 
models exhibited 25% reduction in CSQ2 levels with no effects on other junctional SR 
proteins.  The CASQ+/- model showed spontaneous SR Ca2+ releases, due to an 
increase in diastolic SR Ca2+ leak that was similar to changes seen in some CPVT 
models [122] that is; dysregulation of Ca2+ release. 
Thus, mice with chronic changes in CSQ2 appear to develop general 
malformation of Ca2+-release complexes.  Functional changes reported in these mice, 
however, may not be useful models for deciphering the functions of cardiac CSQ2.  
Nevertheless, studies of heterozygote mice (CASQ2+/-) that exhibited roughly 25% 
reductions in CSQ2 levels may be useful since the generation of a so-called “diastolic 
leak” supports a function for CSQ2 in regulating the closing of the RyR2 channel.  A 
significant number of point mutations in human CASQ2 are also associated with a 
recessive form of CPVT [123, 124], and studies have suggested similar clinical 
phenotypes for RyR2- and CSQ2-induced diseases [125].  Moreover, partial knockdown 
of CSQ2 [122] also leads to a phenotype similar to CPVT, supporting a major role for 
CSQ2 in regulation of RyR. In depth studies of the first reported mutation in CSQ2 
(D307H) showed that the mutant protein was not capable of undergoing the appropriate 
conformational changes for the Ca2+ concentrations expected to occur inside junctional 
SR lumens, nor was it capable of binding efficiently to its target proteins JCT and 
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TRD[126].  
1.7 Cytoskeleton 
1.7.1 Cardiac cytoskeletal components 
The integrity of cardiomyocytes is maintained by the cytoskeleton, which is 
divided morphologically into nuclear, membrane-submembrane, sarcomeric and extra-
sarcomeric [127].  The nucleus is supported by a nuclear lamina, located below the 
inner nuclear membrane and consisting of a dense network of intermediate filaments, 
lamins, and interacts with both chromatin and the nuclear envelope.  This whole 
complex is connected to the extra-sarcomeric cytoskeleton, actin, and T-tubules [128].  
The membrane-submembrane cytoskeleton serves as the connection between 
sarcomeres and sarcolemma, and consists of the focal adhesion proteins (vinculin, talin 
and integrin), spectrins (spectrins, ankyrin and 4.1 proteins) and the dystrophin-
dystroglycan complexes [138]. 
The sarcomeric cytoskeleton consists of thin filaments (cardiac beta- and 
gamma-actin, C- I- and T-troponins and alpha-tropomyosin), thick-filaments (myosin 
and myosin binding proteins C, H and X) and the Z-disk.  The sarcomere, extra-
sarcomeric cytoskeleton and the sarcolemma meet at the Z-disk.  The extra-sarcomeric 
cytoskeleton is composed MTs, intermediate desmin filaments and actin microfilaments 
[138].   
1.7.2 Microtubules and endoplasmic reticulum 
Electron microscopy shows a close relationship between ER tubules and MTs, 
where they are closely parallel over considerable distances [139, 140].  Furthermore, 
evidence from studies utilizing live cell imaging show that MTs drive ER tubule 
extension.  Tubule extension is mechanistically achieved in three distinct ways: 
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association between ER and the (+) end of MTs through tip attachment complexes 
(TAC), sliding of ER membrane on MTs that move through the cell as an intact entity, 
and a more predominant and faster motor driven movement [141-143].  
In vitro formation of ER tubules and network can be generated without the 
cytoskeleton [144], thus, MTs are essential more in ER tubule extension and movement 
than formation [145].  In vivo, stable interactions between MTs and ER associated 
proteins are important for the ER network [146].  
1.7.2.1 Microtubules 
MTs are hollow cylindrical structures (diameter 24 nm), built from 13 parallel 
protofilaments.  They are composed of repeated heterodimers of 55 kDa α- and β-
tubulin globular proteins. α- and β-tubulin molecules are homologous but not identical, 
each comprises several isoforms and, thus can have distinct locations in the cell, and 
perform different functions [127].  MTs are dynamic where they undergo phases of 
growing and shrinking.  The binding and hydrolysis of GTP by tubulin subunits is known 
to lead to dynamic instability of the MTs [147].  
MTs form a network that spans transversely and longitudinally along the 
cardiomyocyte axis and densely around and between nuclei [140, 148].  More generally, 
MTs play a role in maintaining cell integrity [149] and are involved in organelle transport 
[150], protein synthesis, and intracellular transport [151, 152].  Studies on membrane 
ion channels in cardiomyocytes support the role of MTs in ion channel delivery [153, 
154].  
1.7.2.1.1 Microtubule disrupting agents 
MT depolymerizing agents cause a drastic alteration in the morphology of the 
ER.  Studies have demonstrated that many intracellular events rely on proper ER 
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network morphology.  Mutations in proteins that localize to ER, identified in a class of 
neurological disorders underscore the medical importance of understanding intracellular 
membrane protein trafficking and localization that allow the ER to serve its 
multifunctional roles.  
Nocodazole (methyl [5-(2-thienylcarbonyl)-1H-benzimidazol-2-yl]) is a synthetic 
compound that depolymerizes MTs and inhibits tubulin self-assembly [155].  
Nocodazole acts through inhibition of polymerization of tubulin subunits, leading to de-
polymerization of dynamic microtubules [156, 157].  ER network collapse towards the 
center of the cell and the formation of sheet-like structures has been demonstrated 
upon nocodazole depolymerization of the MTs [158, 159].  
1.8 Adenovirus mediated overexpression in cardiomyocytes 
Several key characteristics of neonatal and fetal cardiac myocytes such as the 
dynamic culturing nature, expression of signaling molecules, transcription factors, Ca2+ 
handling protein isoforms and morphological and sarcomeric organization have made 
difficult the extrapolation of data to adult cardiac myocytes [160-162].  Therefore, in vitro 
gene transfer through viral vectors to isolated adult cardiomyocytes is a powerful 
experimental approach in understanding structure and function.  
Adenovirus is a member of the Adenoviridae class of viruses.  The Ad vectors 
are one of the most efficient methods for in vivo and in vitro transduction.  The most 
commonly used biomedical reagents are engineered replication-deficient serotypes Ad 
2 and 5, where CMV promoter drives foreign gene expression.  The adenovirus virion 
consists of a proteinacous capsid that surrounds the double-stranded DNA, and vertices 
that serve to attach the virus to the host cell membrane containing coxsackievirus 
(CAR) or adenovirus receptors [163].  Once the Ad is endocytosed, the double stranded 
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DNA migrates to the nucleus and is transcribed [164].  
In the studies described in Chapter 4 and 5, expression of canine junctional SR 
proteins was performed at comparable levels to endogenous proteins in cultured adult 
rat cardiomyocytes using Ad vectors, driven by CMV promoter.  
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CHAPTER 2 
MATERIALS AND METHODS 
2.1 Animals and heart tissue 
The investigation conforms to the Guide for the Care and Use of Laboratory 
Animals published by the US National Institutes of Health (NIH Publication No. 85-23, 
revised 1996).  The studies performed using Sprague-Dawley (Rattus norvegicus) rats 
(Harlan Laboratories, IN) were approved by the Wayne State University Animal 
Investigation Committee (Appendix B).  
Heart tissue was obtained from sham-treated control dogs (C) and dogs in heart 
failure (HF) as frozen samples saved in liquid N2.  Ischemia-induced HF (HFi) was 
induced by multiple sequential intracoronary embolization’s with microspheres 
performed in mongrel dogs 1-3 weeks apart over 6 months, and was discontinued when 
left ventricular (LV) ejection fraction was ≤35%, as previously described [165], and 
animals were sacrificed after 3 additional weeks.  Samples of the posterior wall from the 
LV were stored at -80 oC, and thawed prior to tissue homogenization.  For tachypacing-
induced HF (HFt), LV dysfunction was induced by rapid ventricular pacing in mongrel 
dogs at >180 beats/min for >4 weeks to produce HF (ejection fraction ≤ 35%), and 
animals were generally sacrificed within 1-3 weeks [166].  Samples of LV posterior wall 
and septum were removed, and stored in liquid N2.  Samples of frozen tissue used in 
the present studies were thawed prior to tissue homogenization. 
2.2 Purification of CSQ2 
CSQ2 was purified from frozen tissue samples (2-5 g) as previously described 
[167, 168].  Briefly, heart tissue samples were homogenized using Polytron 
homogenizer (PT 10-35) at speed 5 for 30 sec in a Buffer A pH 8.0 containing 15 mM 
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Tris Base, 200 mM NaCl, 0.5 mM EGTA and a phosphatase inhibitors mixture of 5 mM 
NaF, 5 mM Glycerol 2-phosphate Disodium salt Hydrate and 5 mM NaPPi, were added 
to the homogenate.  Triton X-100 was then added to the homogenate at 1%. 
Homogenates were then transferred to centrifuge tubes and centrifuged using Sorvall 
RC 5B PLUS (SS-34 rotor) at 35,000 x g for 45 min after which supernatants were 
collected.  
The collected supernatant was then applied to an anion exchange 
chromatography column of DEAE-sephacel (Diethylaminoethyl Sephacel© (Sigma 
I6505).  The column was then washed with several volumes of Buffer A pH 8.0 
containing 220 mM NaCl and 0.5% Triton X-100 then followed by Buffer A pH 8.0 
containing 220 mM NaCl.  A salt dependent elution was then performed with Buffer A 
pH 8.0 containing 700 mM NaCl (Buffer B).  
The collected elutions were then applied to a column of phenyl-Sepharose CL-4B 
(Sigma P7892) equilibrated with Buffer B pH 8.0.  The column was then washed with 
several volumes of Buffer B to remove contaminants.  A Ca2+ dependent elution was 
then performed using Buffer B with 20 mM CaCl2.  Spectrophotometry was performed at 
280 nm on the collected elution fractions.  The protein samples were then desalted by 
repeated washes with HPLC grade water (Fisher Scientific) through centrifugal filters 
(Amicon® Ultra-0.5 ml 10K, Millipore UFC501096). Concentrated fractions (1 g) was 
run on acrylamide gel and visualized using Coomassie® Blue stain on gel (section 
2.5.2).  
2.3 Cardiomyocyte isolation  
2.3.1 Surgery 
Hearts were obtained from male Sprague Dawley rats weighing between 175-
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200 g.  Following standard protocol the animals were anesthetized with 300 mg/kg 
bodyweight by peritoneal injection of 5% Avertin (tribromoethanol) working solution in 
PBS (Sigma, P4417).  The working solution was prepared from a 50% stock of 2,2,2-
tribromoethanol (Sigma T48402) dissolved in 2-methyl-2-2butanol (Sigma 240486).  
The incision area was sterilized using 70% ethanol.  The chest was opened and the 
heart was excised with a large portion of the aorta intact and placed immediately in cold 
solution A (described In section 2.3.2).  
2.3.2 Isolation protocol  
Cardiomyocytes were isolated by retrograde perfusion using the Langendorff 
apparatus [169].  Briefly, the heart was hung with the aorta clamped and tied with a 
suture to a 1.8 mm aorta cannula (Radnoti 140153-16), to ensure good perfusion the 
aorta was not pushed too far into the heart.  Perfusion with warmed/oxygenated Ca2+-
free solution A containing 10.0 mM HEPES (Sigma H-4034), 1.2 mM KH2PO4, 5.0 mM 
Pyruvic acid (Sigma P5280), 110.0 mM NaCl (Sigma S6191), 1.2 mM MgSO4 (Sigma 
M2643), 5.0 mM creatine (Sigma C3630), 4.8 mM KCl (Sigma P5405), 11.0 mM 
Glucose (Sigma G7528) and 5.0 mM taurine (Sigma T8691) was carried out for 5 min. 
to wash out the heart.  Enzymatic dissociation was then carried out using solution A with 
5 mg Liberase TM Research Grade (Roche 05401127001) and 0.1 mM CaCl2 (Sigma 
C7902).  After 15-20 min of enzymatic digestion, the ventricles were cut from the 
cannula and placed in a dish along with the enzyme containing solution A in a 37 oC 
water bath for 10 min for further enzymatic digestion.  The mixture was then filtered 
through nylon mesh into a 50 ml Falcon conical tube.  The filtrate was spun in swinging 
bucket centrifuge for 2 - 5 min at ~1200 rpm until a light pellet formed.  The cell pellet 
was resuspended with solution A containing 250 μM CaCl2, centrifuged for 2 - 5 min at 
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~1200 rpm until a light pellet formed, supernatant was discarded and cell pellet was 
resuspended with 500 μM CaCl2 centrifuged for 2 - 5 min at ~1200 rpm until a light 
pellet formed, supernatant was discarded and cell pellet was resuspended as described 
below (section 2.3.3).  
2.3.3 Cardiomyocyte culture  
Cells were resuspended in Medium 199 (Invitrogen 12340-030) containing 2% 
bovine serum albumin (Sigma A1933), 2 mM carnitine (Sigma C0283), 5 mM creatine 
(Sigma C3630), 5 mM taurine (Sigma T8691), 2 mM L-glutamine, 2 mM Glutamax-1 
(Invitrogen 35050-061), 25 M blebbistatin (Toronto Research Chemicals B592500), 1% 
Penicillin-Streptomycin (Invitrogen 15070-063), 1% ITS (Sigma I3146), 2 mM L-
glutamine (Sigma G7513), 1% MEM non-essential amino acids (Invitrogen 11140-050).  
The cells were examined under the microscope (Nikon Eclipse TS100) and then stained 
with trypan blue (0.4%) (Sigma T8154) and counted using hemacytometer (Reichert) for 
plating.  The isolated cardiomyocytes were plated in 6-well dishes (50,000 cells/well) 
containing coverslips coated with laminin (Sigma L2020) at 37 °C with 5% CO2 and 
cultured up to 48 h. 
2.4 Cell treatments 
2.4.1 Adenovirus infection 
Adenoviral CSQ2-DsRed (Ad.CSQ2-DsRed), CSQ2 (Ad.CSQ2), TRD (Ad.TRD) 
and JCT (Ad.JCT) vectors were previously described [84, 170, 171].  To determine the 
virus concentration (plaque forming units, pfu/l), HEK 293 cells (ATCC) were plated at 
0.2 x 106 cells/well and the viruses were added the next day as follows: 10, 3, 1, 0.3, 
0.1, 0.03, and 0 µl.  For the purposes of estimating a concentration we assumed that 
100% decimation of the cells was a multiplicity of infection (MOI) of 1.  This assumption 
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was frequently checked by commercial assays.  Calculation of pfu/cell was determined 
based on viable rod shaped cardiomyocytes not total cell count.  
As previously described [19], adenoviruses were added directly to dishes 2 h 
post-plating at MOI=200 (1x).  In Chapter 5, the cardiomyocytes were infected with up to 
5x Ad.CSQ2 in order to visualize the initial sites of accumulation following its protein 
synthesis.  For all adenoviral studies, treatments were carried out for 12 or 16, 24, 30 
and 48 h as indicated before harvesting for biochemical analysis and fixing of coverslips 
for microscopy. 
2.4.2 Nocodazole treatment 
Nocodazole (Sigma M1404) (20 M) was diluted in Medium 199 and added to 
cardiomyocytes 16 h post-plating.  Cardiomyocytes treated (+) with nocodazole up till 32 
h in culture where as cells cultured under similar conditions without nocodazole (-), 
served as control.  Cells were fixed for immunofluorescence studies after 48 h in 
culture.  Treatments with nocodazole for last 2 h prior to harvesting and fixation, 
however, did not show any marked disruption.  Therefore, we opted to add nocodazole 
12-16 h post-plating (Appendix C Figure A-3).  
2.5 Electrophoresis  
2.5.1 Protein extraction and concentration determination 
Protein extraction from cultured cardiomyocytes was performed as follows, 
immediately after removal of coverslips for immunofluorescence analysis (see section 
2.6.3.1), 6-well dishes were placed on ice and cells were scrapped and transferred with 
media into 15 ml Falcon conical tubes.  The cells were centrifuged using ADAMS 
DYNAC centrifuge (Clay Adams Inc.) for 10 min at 4 oC and media was discarded.  The 
cell pellet was resuspended with PBS and centrifuged at the same settings.  
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Supernatant was again discarded and cell pellets were resuspended with 200 µl 
extraction buffer (10 mM Tris, 200 mM NaCl, 1% triton X-100, 0.5 mM EGTA, pH 8.0), 
centrifuged after which protein extracts were collected and saved in -80 oC for later 
determination of protein concentration by Lowry assay [172] and electrophoretic 
analysis.  
2.5.2 Gel electrophoresis  
SDS-PAGE was carried out according to Laemmli [173] on 7% or 10% 
acrylamide gels using Hoefer® GE600 Chrome apparatus (Amersham) or on 10% Bis-
Tris MIDI gels (Invitrogen) according to manufacturer. Gels were transferred to 
nitrocellulose membranes (0.45 m, BioRad Laboratories) and stained with Amido Black 
(Sigma). 
2.5.3 Concanavalin A binding to glycoproteins 
Similar amounts of purified CSQ2 from heart samples were analyzed by 
immunoblotting based on immunoblot quantification.  Duplicate nitrocellulose strips 
were then analyzed by immunoblotting (section 2.6.2) or Con A binding.  For Con A 
binding to CSQ2, one strip without prior non-specific protein blocking of membrane was 
incubated in phosphate buffer saline with 0.2% tween20 (PBS/tween) containing Con A 
conjugated to peroxidase (Sigma, L6397) at 10 μg/ ml for 90 min at room temperature 
[174].  The strip was rinsed three times for 5 min each, and then developed using 
enhanced chemiluminesence (ECL) reagents (Pierce 32106).  ECL and quantitation of 
digitized scans were performed to determine Con A binding/μg CSQ2 using ImageJ 
(Wayne Rasband, National Institutes of Health). 
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2.6 Immunological methods 
2.6.1 Antibodies  
Antibodies used in immunoblotting and immunofluorescence assays were as 
follows: anti-CSQrat (Abcam ab3516), anti-CSQdog, anti-JCTdog and anti-JCTrat antibodies 
were the generous gift of Dr. Larry Jones, Indiana University School of Medicine. 
Monoclonal anti-CSQ2 antibodies used for assays in Chapter 2 are previously 
described [85].  Anti-TRDdog antibodies were as previously described [175], anti-TRDrat 
were purchased from Thermo (MA3-927).  Tubulin antibodies were as follows: anti-
alpha tubulin (Sigma T6074) and anti-beta tubulin (Sigma T5201).  Alexa Fluor 488 or 
568 conjugated goat anti-rabbit IgG, Alexa Fluor 488 or 568-conjugated goat anti-
mouse IgG secondary antibodies were purchased from Invitrogen.  Relative 
specificity/selectivity of the antibodies used towards dog or rat junctional SR proteins 
indicated by (+) or (-) are shown in Table 2-1.  
Table 2-1. Relative reactivity of junctional SR protein antibodies to dog or rat forms.  
 
2.6.2 Immunoblot 
Immunoblotting was carried out as previously described [176].  Briefly, the 
nitrocellulose membranes were blocked with 1 mg/ml bovine serum albumin in 
             
Protein Target  Antibody Dog Rat
anti-TRDdog  +  - polyclonal
anti-TRDrat  -  + monoclonal
anti-JCTdog  ++  - monoclonal
anti-JCTrat  +  ++ polyclonal
anti-CSQdog  ++  - monoclonal
anti-CSQrat  +  ++ polyclonal
Species Reactivity
 TRD
 JCT
CSQ
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PBS/tween for 15 min and then incubated with primary antibodies solution in PBS/tween 
for 90 min and then washed three times with 15 min.  Primary antibody dilutions were 
adjusted to assure that ECL signals for multiple antigens on a single exposure of film 
remained within a linear range.  Membranes were then incubated in PBS/tween with 
horseradish peroxidase-conjugated goat anti-rabbit IgG and goat anti-mouse IgG 
secondary antibodies (1:30,000) (Jackson ImmunoResearch Laboratories) for 45 min 
and then washed with PBS/tween.  ECL reagent was used to detect immune 
complexes, which were then visualized by autoradiography using high resolution 
Amersham Hyperfilm ECL film (GE Healthcare).  Autoradiograms were quantified using 
ImageJ.  
2.6.3 Immunofluorescence 
2.6.3.1 Immunocytochemistry on isolated cardiomyocytes  
Briefly, cells grown on coverslips were fixed with 4% paraformaldehyde in PBS 
for 15 min and then permeabilized for 10 min in 0.2% PBS/tween.  Coverslips were 
blocked in PBS with 0.2% Tween-20 (PBS/Tween) and 2% goat serum at room 
temperature for 20 min.  Cells were then incubated in PBS/Tween with primary antibody 
(1:100) overnight at 4°C, followed by washing in PBS/Tween, and incubation with goat 
anti-rabbit IgG or goat anti-mouse IgG antibodies conjugated to Alexa Fluor dyes (1:100 
dilution in PBS/Tween for 120 min).  Cells were counterstained with NucBlue Fixed Cell 
ReadyProbes Reagent (Molecular probes R37606) for 30 min. rinsed, and mounted to 
microscope slides with ProLong Antifade Mounting Kit (Molecular Probes).  
2.6.3.2 Immunohistochemistry on tissue sections 
Frozen LV tissue from C and HF hearts were removed from liquid N2 and 
embedded in OCT compound, sliced by cryostat (-21 °C, 10 m thickness), and dried 
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on Superfrost® Plus Gold slides (Fisherbrand).  The slices were hydrated in PBS and 
the OCT washed three times in PBS at RT.  Fixation was performed with 4% 
paraformaldehyde in PBS for 15 min, and washed three times, then blocked with 1% 
goat serum in PBS-tween for 4 h; all carried out at ambient temperatures.  Antibodies 
were premixed before use to attain uniform distributions.  The primary antibody mixture 
contained 1:50 dilutions of mouse anti-CSQ2 monoclonal (mAb) 4E7 and rabbit anti-
CSQ2 polyclonal (pAb), and was applied for 24 h at 4 °C.  Equal volumes of the two 
antibodies contained roughly equivalent ECL signals against purified canine CSQ2 
using the same respective anti-IgG goat antibodies used for immunoblotting.  Slides 
were than washed three times for 5 min.  The secondary antibody mixture contained 
1:200 dilutions of goat anti-mouse Alexa Fluor 488 (Invitrogen) and goat anti-rabbit 
Alexa Fluor 568, and was applied 4h at RT.  Slides were then washed three times for 15 
min in PBS/tween, RT, stained with 100 µM 4′-6-diamidino-2-phenylindole (DAPI) for 2 
min, and washed for 10 min in PBS/tween, RT.  Coverslips were mounted for imaging 
using a drop of ProLong Gold Antifade (Invitrogen).  
2.7 Fluorescence microscopy 
Imaging of tissue and cardiomyocytes was performed using a 63 ×/1.4 oil 
objective on a Leica DMI 6000B system.  All confocal images were acquired at the 
same settings and were concurrently processed and optimized offline for publication 
using Photoshop (Adobe Systems Inc.).  Fluorescence intensity quantification was 
performed using ImageJ (Wayne Rasband, National Institutes of Health).  
Transverse lines of 50 pixels were used to select areas that extended from the 
cell edges and included the center of one nucleus (in tissue staining) and to the edge of 
the nucleus (in cell immunostaining).  The intensity of each color channel was plotted 
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(red: pAB-CSQ-2, green: mAB-CSQ-2, blue: DAPI) in consecutive 3-μm steps distance 
from the nucleus.  Values are plotted as fractional deviations from the average 
fluorescence intensities for each channel.  Channel values were standardized for 
plotting using Microsoft Excel.  
2.8 Quantitative PCR 
RNA extraction from heart samples was performed using RNeasy Fibrous tissue 
Mini Kit (Qiagen).  One microgram of DNase-treated total RNA sample was reverse 
transcribed by reverse transcription (Applied Biosystems).  Quantitative PCR with fast 
SYBR green (Applied Biosystems Step One with v2.0 software) was performed using 
canine specific primers designed to span one intron.   Canine primers were as follows:  
GAPDH: forward, CCCCTTCATTGATCTCAACTACATGGT 
                 reverse, CCCGTTGATGACAAGTTTCCCGTTC-TC 
CSQ2: forward, CCAAGCTTGCCAAGAA-GCTGGGT 
      reverse, ACGTCAGCTGCAAACT-CGCCA 
ANF: forward, AGAGCGGACTGGGC-TGCAACA 
           reverse, CCCAAGGGACGAGGGT-CTCTCA 
BNP: forward, ACTACGCAGCCCC-AAGATG 
            reverse, CCTCAGCACTTTGCAGC-CCA 
Relative quantitation method (∆Ct) was used to evaluate mRNA levels for CSQ2, 
along with hypertrophic markers atrial natriuretic factor (ANF) and brain natriuretic 
peptide (BNP).  Fold change (2-ΔCt) relative to glyceraldehyde 3-phosphate 
dehydrogenase (GAPDH) mRNA levels was used. GAPDH mRNA levels were highly 
similar between C and HF samples. 
2.9 Mass spectrometry  
In order to measure the mass to charge ratio (m/z) mass spectrometry was used.  
Small highly charged droplets are formed by electrostatic dispersion of protein solution 
through a glass capillary subjected to a high electric field.  In order to calculate the 
molecular weight of a particular peptide, the observed m/z ratio has to be corrected for 
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(multiplied by) the number of attached protons [177].  Electro spray ionization mass 
spectrometry of purified CSQ2 (ESMS) was performed at the Keck Biotechnology 
Laboratories, Yale University, New Haven, CN using a Q-ToF mass spectrometer 
(Micromass, Altrincham, UK), as previously described [167].  Protein samples were 
resuspended or diluted in 20% acetonitrile, 0.1% formic acid.  The proteins were 
trapped on a Michrom (Auburn, CA) protein cap trap using a Waters (Milford, MA) 
CapLC.  Trapped proteins were eluted into a Waters Q-Tof Ultima mass spectrometer 
and their masses deconvoluted using the MaxEnt1 algorithm. 
2.10 Statistical analysis 
Data are presented as mean ± SEM. To determine differences between C and 
HF groups, Student’s t-tests were performed, and P<0.05 was considered statistically 
significant. Microscopy data for tissue slices from two hearts as mean ± SD. 
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CHAPTER 3 
ALTERED CALSEQUESTRIN GLYCAN PROCESSING IS COMMON TO DIVERSE 
MODELS OF CANINE HEART FAILURE 
3.1 Rationale  
The N-linked glycan in CSQ2 from mammalian heart tissue normally undergoes a 
high degree of trimming by intracellular mannosidases.  Minor differences in CSQ2 
glycan structures have been previously noted in larger mongrel dog hearts [167] 
compared to that of purebred beagles [178].  Interestingly, in beagles, CSQ2 glycans 
exhibit a dramatic reduction in mannose trimming following a 6-8 week period of 
tachypacing that produces HF [178].  To determine whether this is an effect specific to 
the smaller animal or to a single type of cardiac stress, we broadened such 
investigations to include two diverse experimental models of HF in the mongrel dog.  
We report here that whether dogs receive ventricular tachypacing or are placed into 
failure by ischemia due to recurring coronary microembolizations, dramatic and 
qualitatively similar alterations of CSQ2 processing occur wherein normal CSQ2 is 
replaced in HF tissue with protein that has not undergone the same degree of 
posttranslational processing. 
Hypothesis: CSQ2 trafficking within the cardiomyocytes is dramatically altered in 
mongrel canine populations using two of the leading models of heart failure induction 
3.2 Results 
3.2.1 Analysis of CSQ2 glycoforms and phosphoforms 
Purified CSQ2 analyzed using ESMS resolves CSQ2 into its polymorphic 
spectrum of masses and provides quantification of individual CSQ2 molecular 
structures.  Detailed knowledge regarding mannose trimming of its 316Asn-linked glycan 
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can be deciphered from these mass spectra, which undergo loss of mass in 162 Da 
steps that are indicative of mannose trimming [167].  Superimposed upon the mass 
change for each glycoform can be additional mass changes due to changes in CSQ2 
phosphorylation on its C-terminus (378,382,386Ser).  The exact state of phosphorylation for 
a given glycoform is obscured by the coincidental overlap in mass changes resulting 
from mannose trimming (Δmass = 162 Da) and that resulting from differences from two 
phosphates (2 x 81 Da = 162 Da) [167, 179].  Nonetheless, relatively large and very 
consistent differences in CSQ2 mass peaks were found between control and failed 
heart tissue samples occurring in steps of 162 Da and 81 Da that reflect differences in 
steady-state levels of these two ongoing posttranslational processes.   
Purified CSQ2 from C mongrel dogs exhibited a range of molecular masses, 
having a weighted average of 46,306 Da, a value that is 1037  41 greater than its 
deduced molecular weight of 42,269 (Table 3-1).  CSQ2 masses, 90% of which were 
between 46,001 and 46,487 Da, corresponded to CSQ2 molecules having glycans that 
have undergone processing by intracellular mannosidase(s) to structures 
GlcNAc2Man3-5 (Figures 3-1 & 3-2).  In contrast to the single uniform peak of CSQ2 
masses present in C hearts, every heart from HF dogs contained CSQ2 molecules that 
were less processed, and so were of greater mass.  More striking was the appearance 
of two broad groupings of mass peaks, demarcated Pool I and II (Figure 3-1).  A 
prominent lower mass pool in HFt and HFi (Pool I) was relatively close in mass to the 
single pool of CSQ2 found in C hearts, yet larger by 274  94 and 326  85 Da, 
respectively (Table 3-I).  The highly processed CSQ2 molecules found in all canine 
hearts reflects the successive removal of mannose in more distal subcellular 
compartments, processed by mannosidase(s) beyond that of the early ER [167].  
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Although not structurally identical in C, HFi, and HFt hearts, it is hypothesized that this 
larger pool of highly processed protein in each heart corresponds to junctional SR 
CSQ2.  
Table 3-1. Molecular masses (weighted averages ± S.D.) of CSQ2 from canine heart 
tissue samples (Da) 
 
The second broad grouping of mass peaks (Pool II, Figure 3-1 and Table 3-I) 
was comprised of protein that underwent either no mannose trimming, or removal of a 
single mannose.  This pool of CSQ2 is likely only acted upon by the well-characterized 
ER α-1,2 mannosidase, characteristic of early ER, and known to produce Man8 from 
Man9 [180, 181].  This is the mannose trimming typical of CSQ2 expressed in every 
non-muscle cell examined to date [182].  This higher-mass pool of CSQ2 molecules 
was only present in HF tissue, entirely absent form C mongrel dog heart tissue.  
  Control HF (Tachypacing) HF (Ischemic)
Relative protein amounts     
    Pool I (Man1-Man7 glycoforms)  100 68  20 68  9 
   Pool II (Man8,Man9 glycoforms)  0 32 32 
Weighted mass averages     
    All forms  46,306  41 46,811  116 46,798  196 
    Pool I (Man1-Man7 glycoforms)  46,306  41 46,633  85 46,581   94 
    Pool I (Increase from Control)  N/A ∆AVG = 274  94 ∆AVG = 326  85 
   Pool II (Man8,Man9 glycoforms)  N/A 47,290  88 47,193   30 
47 
	
 
Figure 3-1. CSQ2 masses are altered in heart tissue from mongrel dogs in heart failure. 
a) CSQ2 was purified from control (C) canine heart, and hearts induced into failure by 
repeated microembolisms over 6-9 months (HFi) or by tachypacing (HFt) for 4-8 weeks. 
CSQ2 was purified from frozen tissue samples and intact CSQ2 was analyzed by 
ESMS. Differences in CSQ2 mass isoform peaks correspond to the successive loss of 
mannose sugars (mannose trimming, ∆mass = 162 Da) from the CSQ2 glycan. 
Superimposed on each glycoform are changes in mass brought about by varying 
numbers (0-3) of phosphates on CK2-sensitive sits (∆mass = 81 Da). Masses and 
mannose content are shown across the bottom and top, respectively. CSQ2 mass 
peaks corresponding to Man9,8 glycoforms are shaded.  b) Summary raw data for all 15 
heart samples (12 dog hearts). Mass peaks corresponding to glycoforms and 
phosphoforms are plotted as a percentage of the total (%CSQ2 molecules). Five C 
hearts (green spectra), 3 HFi hearts (red spectra), 4 HFt hearts (blue, posterior wall, 
lavender, septal wall). Shaded area designates rough ER with Man9,8 (Pool II), while 
further mannose trimming is designated as junctional SR (and Pool I). The presumed 
mass of CSQ2 following biosynthesis and folding (mass = 47,478 Da; Man9 with 3 
phosphates) indicated by an asterisk (*). 
Redistribution of CSQ2 molecules from C heart tissue into two mass pools of 
Man1-7 (Pool I) and Man9,8 (Pool II), was further analyzed by calculating separate 
Gaussian distributions based upon the averages calculated from the three cohorts of 
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mongrel dogs (Figure 3-2 panel a).  Here we compared the average molecular masses 
for the two putative CSQ2 pools, along with their relative abundances (relative peak 
heights), and their standard deviations (relative peak width).  Results from the current 
three cohorts of mongrel dog heart samples were also compared with C and HF cohorts 
previously reported for beagles [178].  From these canine heart samples, a general 
pattern emerges wherein CSQ2 from C heart tissue (Figure 3-2 panel a, green curves) 
is consistently comprised of a more highly processed collection of molecules, whereas 
HF tissue has degraded those molecules, and replaced them with less processed, or 
post-translationally "younger", molecules that accumulate in two distinct states of 
posttranslational processing (Figure 3-2 panel a, red curves). 
Because mannose trimming occurs in successive steps, and reflects protein 
biosynthesis, processing, and degradation, the percentage of total CSQ2 remaining at 
each step provides a perspective of its overall turnover (Figure 3-2 panel c).  In C dogs, 
trimming of the first 4 mannoses was not accompanied by any retention, and so 100% 
of CSQ2 molecules proceed to latter steps of mannose trimming.  The first four steps of 
processing correspond to cleavage of (1-2) linkages by an ER (1-2)-mannosidase 
(Figure 3-2 panel b, green circles).  CSQ2 accumulated in the form of molecules with 
additional mannose trimming, with successively fewer molecules of CSQ2 trafficking 
forward.  This analysis suggests that the actions of a second enzyme ((1-3)-
mannosidase) might therefore be associated with the subsequent loss of mannose, 
leading to loss of CSQ2 from the cardiomyocyte.  We cannot determine from the mass 
spectrometric data whether all molecules eventually underwent trimming to Man 3 on 
their path to degradation, or whether all molecules with glycans of Man5-3 were 
degraded directly.  
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Figure 3-2. Further evaluations of CSQ2 mass spectra data. For the analyses shown 
here, the direction of CSQ2 posttranslational processing is reversed from Figure 3-1, 
which reflected the orientation of mass spectrometric data. In panels a, b and d, CSQ2 
processing occurs left to right a) Weighted averages of CSQ2 masses were calculated 
individually for Man9,8 and Man1-7 to construct a model of CSQ2 glycoforms based 
upon low or high levels of mannose trimming (cf. Table 3-1). Control mammalian hearts 
(C) show one peak of highly mannose-trimmed molecules (green peaks). In failing 
hearts (HFi and HFt), the green peak is no longer present, having apparently degraded. 
In its place is found a distinct phenotype exhibiting two CSQ2 pools (red peaks), 
consisting of a prominent pool (Pool II) of poorly processed (Man9,8) protein and a pool 
of junctional SR CSQ2 (Pool I) with glycan processing closer to that of control hearts. 
Similarly modeled are data previously reported in tachypacing of beagle hearts that led 
to HF (Ctb/HFtb) [178]. CSQ2 expressed in non muscle cells [182] produces only ER-
type (Man9,8) CSQ2 (bottom panel) b) Sample structures of CSQ2 protein molecules 
(C-termini) corresponding to masses as indicated. After biogenesis in rough ER, the N-
linked glycan on 316Asn is -GlcNAc2Man9, whereas CK2-sensitive sites (378,382,386Ser) 
are fully phosphorylated, since phosphorylation occurs in the cytoplasm during 
translocation of the nascent polypeptide [183]. Moieties are GlcNAc (black boxes), 
mannoses (blue and green circles) -1,2 linked mannoses (green circles), phosphates 
(red circles). Mannoses and phosphates removed by mannosidases and phosphatases 
are represented by lightened symbols. 
 
3.2.2 Analysis of CSQ2 glycans by Con A binding 
To provide a gel-based assay to corroborate the mass spectrometric analysis of 
CSQ2 glycans, we measured Con A binding to purified CSQ2 on nitrocellulose 
transfers.  Con A is a lectin known to bind to high mannose forms of N-linked glycans 
[174, 184].  CSQ2 from hearts of HFt dogs, but not HFi dogs, bound significantly higher 
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levels of Con A than CSQ2 from C dogs, indicative of the accumulation of the 
unprocessed protein (Figure 3-3 panels a, b).  For tissue samples analyzed both by 
ESMS and Con A binding, a non-linear correlation was found between the percent of 
CSQ2 in Pool II (ER CSQ2) and Con A binding (Figure 3-3 panel c).  This likely 
reflected increased levels of Man9 compared to Man8, but this distinction was difficult to 
confirm by ESMS because of the overlap of mass peaks due to overlap of masses 
resulting from loss of mannose (mass = 162 Da) and phosphate (mass = 81 Da) [185].   
 
Figure 3-3. Con A binding to purified CSQ2 from C and HF tissue samples. a) Con A 
binding to purified CSQ2 on nitrocellulose membranes. Measurements were carried out 
in 3 independent determinations of the same sample, from 16 hearts, including samples 
of HFt posterior wall and septum (LV regions). Averages for each animal cohort of C, 
HFi, and HFt are mean  SEM.; significance (p < 0.05) is indicated by asterisk (*). 
Values for LV regions are mean  SD. b) Sample autoradiograms of CSQ2 antibody 
binding (upper band) and Con A binding (lower band) for C and HFt sample. Data 
shown in panel a is Con A divided by CSQ2 antibody binding, normalized to the values 
obtained for CSQ2 from HEK cells (cf. Figures. 3-1a, 3-2a). c) Comparison of 
percentage of CSQ2 molecules in ER (Pool II glycans) plotted against Con A binding, 
for samples in which both types of data were obtained. 
 
3.2.3 Steady-state CSQ2 protein and mRNA levels 
Total steady-state levels of CSQ2 protein were measured in tissue homogenates 
from C, HFi, and HFt mongrel dogs.  Decreased total levels of CSQ2 were found in both 
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HF dogs compared to C (Figure 3-4 panels a, b) with mean levels of CSQ2 reduced in 
HFi and HFt by 86% and 58%, respectively, although neither was statistically significant.  
Data were also obtained for CSQ2 mRNA levels in HFi and HFt.  Compared to C hearts; 
mRNA in HFi and HFt was increased by 33% and 72%, respectively (Figure 3-4 panel 
c).  Only changes in CSQ2 mRNA levels in HFt dogs attained statistical significance 
(p=0.04). 
 
Figure 3-4. Steady-state levels of CSQ2 protein, mRNA, and protein to mRNA ratios in 
canine hearts. Total numbers of dogs were: C, n=6; HFi, n=5; HFt, n=5. Samples from 
each dog were measured a minimum of four times. a) Canine heart homogenates were 
analyzed by immunoblotting (30 μg/lane). Representative immunoblot data: Amido 
black-stained nitrocellulose (Protein Stain) and autoradiogram for α -actinin and CSQ for 
C, HFi and HFt. Molecular weight markers (left margin) are in kDa. b) Summary data for 
C, HFi and HFt dogs normalized to α-actinin as loading control. Values are from 3 
measurements for 5 dogs (mean  SEM, p-values for t-test, significance < 0.05 
indicated by asterisk (*)). c) Data for levels of mRNA for CSQ2, ANF, and BNP, 
determined by quantitative PCR for C, HFi, and HFt dogs (mean  SEM, p values for t-
test; significance < 0.05 indicated by asterisk (*)).  Values on right correspond to ANF 
and BNP mRNA levels. d) CSQ2 protein to mRNA ratios calculated for each dog, and 
averaged for C, HFi, and HFt dogs (mean  SEM, p values for t-test; significance < 0.05 
indicated by asterisk (*))   
Transcript levels for ANF and BNP were also determined as a measure of 
hypertrophy in C, HFi, and HFt groups.  Mean values for these two markers were highly 
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increased in both HFi (ANF, 16-fold; BNP, 51-fold) and HFt (ANF, 18-fold; BNP 96-fold) 
tissues compared to C (Figure 3-4 panel c).  The increase in dog HF samples, while 
very large, did not attain statistical significance, as large variations in transcript levels 
were measured for individual dogs.  Reasons for variability were not further 
investigated.  
Since protein levels showed a tendency to decrease, in spite of increased mRNA 
levels, we determined protein levels per mRNA levels, averaged for each dog (Figure 3-
4 panel d).  For HFt dogs, this measure of protein/mRNA was reduced by 3.0-fold 
(p=0.003), whereas a lesser but not significant reduction was found for HFi dogs 
(p=0.08).  
3.2.4 Immunohistochemical analysis of canine tissue 
Given the roughly one-third of CSQ2 that accumulates in an unprocessed form in 
cardiac HF tissue, we tested whether this separate mass pool of CSQ2 might be 
apparent by immunohistofluorescence microscopy.  The rough ER responsible for 
CSQ2 biosynthesis is thought to localize to membranes surrounding myonuclei, based 
upon studies of CSQ2-DsRed overexpression in cultured adult rat cardiomyocytes[117]. 
To determine whether there was enhanced CSQ2 immunofluorescence relative 
to myonuclei in HF compared to C tissue, we analyzed thin sections of heart from C 
tissue and from two different HFt tissue samples.  HFt samples were chosen that 
exhibited high levels of ER-CSQ2 by ESMS.  Quantitative analysis of confocal 
immunofluorescence from C and HFt tissue, showed no significant differences in 
relative CSQ2 levels across the cardiomyocyte (Figure 3-5).  
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Figure 3-5. Detection of CSQ2 in 
canine tissue slices by 
immunofluorescence, and CSQ2 
antibody reactivity. Tissue sections 
were analyzed by 
immunofluorescence using a 
mixture of polyclonal (poly, Red) 
and monoclonal (mono, Green) anti-
CSQ2 antibodies, each diluted 1:50. 
Images were obtained as a series of 
optical slices (Z-stack), and single 
confocal images were selected for 
quantitation, as described in 
Methods a) Bar graphs show 
integrated intensities of 
fluorescence signals across a 
transverse width for 12 individual 
cells from five separate Z-stacks 
obtained for two different left 
ventricle tissue slices. Values are 
total fluorescent intensity over 
background (lowest intensity per 
channel), averaged for all 12 cells 
(mean intensity in each 3-μm 
window for red or green channel 
SD).  Scale bar, 3 μm. b) Relative 
immunoreactivity for roughly 
equivalent IgG concentrations of the 
two antibodies. Lane 1, 1.0 μg 
purified canine CSQ2 from HEK 
cells, which contains ~1.5 mol 
phosphate on C-terminal sites and a 
glycan of structure -GlcNAcMan9,8 
[167, 182]; lane 2, 1.0 μg purified of 
CSQ2 phosphorylation-site negative 
mutant Ser(378,382,386)Ala from 
HEK cells [183]; lane 3, 1.0 μg purified CSQ2 from Control canine ventricular tissue, 
which contains ~1.5 mol phosphate on C-terminal sites and an N-linked glycan of 
structure –GlcNAcMan4-6 ([179] and Figure 4). c) Sample confocal fluorescence 
images from C and HFt tissue slices. Scale bar 3 μm. Enlarged field (white inset) 
showing minor differences in immunoreactive localization. Scale bar 1 μm.    
Interestingly, our data also supported the idea that there is more than a single 
homogeneous pool of CSQ2 within canine cardiomyocytes.  Commercial anti-CSQ 
polyclonal antibodies produced the expected intense punctate immunofluorescence, 
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whereas canine-CSQ2-selective monoclonal antibody produced a similar but clearly 
distinct immunofluorescence (Figure 3-5 panel c).  These differences in apparent 
subcellular localization were most likely due to differences in accessibility of the epitope 
for the monoclonal antibody (264EFLEILKQV), not to selective posttranslational changes. 
Immunoblot analyses of relative CSQ2 immunoreactivities for the two antibodies 
showed that neither the polyclonal nor monoclonal antibodies exhibited differences in 
CSQ2 immunoreactivity that stemmed from its level of endogenous phosphate or its 
degree of glycan processing (Figure 3-5 panel b).  This was tested by comparing 
reactivities against recombinant canine CSQ2 from HEK cells, in which little mannose 
trimming occurs [186], or a phosphorylation-site mutant Ser(378,382,386)Ala [183], or 
CSQ2 from C dog heart which contains phosphate and undergoes substantial mannose 
trimming.  
3.3 Summary 
In this chapter, we have shown that the prevalent form of CSQ2 glycans in 
normal dogs is absent in HF dogs and is replaced with two new pools that accumulate 
with different forms of the glycan.  The most unprocessed form of CSQ2 accumulated to 
as high as 40% of total CSQ2 in only weeks of the induced cardiomyopathy.  The most 
highly trimmed forms of CSQ2 were virtually absent in HF animals, indicating that CSQ2 
was not processed as HF ensued and by the time the tissue was harvested (4 weeks or 
greater) (Figure 3-2 panel a).  Whether complete loss of this highly processed CSQ2 in 
failing hearts was due to normal attrition could not be determined from the data.  
Nevertheless, in place of normal low-mass CSQ2, two higher-mass forms of CSQ2 
accumulated in HF (Figure 3-2 panel a).  Given the altered patterns of CSQ2 
processing, and the reduction in CSQ2 protein levels, and the increase in mRNA levels 
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(Figure 3-3 panel b), the data infer an increased breakdown of CSQ2 in HF.   
A better understanding of basic ER/SR protein traffic in adult cardiomyocytes is 
needed for interpreting the changes in CSQ2 we found in vivo.  In Chapters 4 and 5, we 
therefore examined where within the cell are found newly formed junctional SR proteins.  
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CHAPTER 4 
SORTING AND TRAFFICKING OF JUNCTIONAL SR TRANSMEMBRANE 
PROTEINS ACROSS ER ALONG MICROTUBULES 
4.1 Rationale  
SR subdomains form at sites where protein complexes concentrate [26, 187].  In 
myocytes, atypical intracellular structure has prevented a clear understanding of the 
routes by which ER/SR compartments form and are dynamically maintained.  
Relationships between the inner membrane subcompartments in cardiomyocytes have 
historically been more defined by ideas of Ca2+ cycling within the cell than by their cell 
biological compartmentation or biogenesis.  Studies do suggest that even at steady 
state, the SR is a dynamic structure, and its motility is regulated by MTs and the 
molecular motors dynein and kinesin (kif5b) [188].  Previous studies using the fusion 
protein CSQ2-DsRed suggested that its biosynthesis was in or near the nuclear 
envelope [116, 117]. 
To investigate cellular mechanisms for sorting and trafficking proteins to 
junctional SR, we expressed canine forms of JCT or TRD in adult rat cardiomyocytes.  
Protein accumulation over time was visualized by confocal fluorescence microscopy 
using species-specific antibodies.  
Hypothesis: Junctional SR transmembrane proteins TRD and JCT synthesis occurs in 
juxtanuclear rough ER and traffics along ER and MT pathways to accumulate in 
junctional SR  
4.2 Results 
4.2.1 Species-specific antibodies to junctional SR transmembrane proteins 
To validate the relative immunoreactivities of antibodies used in this study, we 
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tested relative specificities by immunoblotting against samples from canine and rat heart 
microsomes.  Anti-JCTdog and anti-TRDdog antibodies exhibited complete specificity to 
the canine forms (Table 2-1 and Figure 4-1).  These antibodies would therefore permit 
the specific detection of acutely expressed canine junctional SR proteins from the 
steady-state levels of the native rat heart protein forms.  Meanwhile, rat forms JCTrat 
and TRDrat can be detected using a second set of antibodies, although anti-JCTrat 
detected both forms.  We found minor species-specific differences in TRD mobilities but 
not JCT (Figure 4-1 panel C).  
Figure 4-1. Specificity of anti-TRD and anti-JCT antibodies. Samples (50 g) of canine 
heart microsomes (MVc), rat heart microsomes (MVr) and primary rat cardiomyocytes 
(HCr) were analyzed by SDS-PAGE (10% acrylamide) and transferred to nitrocellulose. 
(A) Amido black stained nitrocellulose, molecular weight markers in kDa. (B) 
Immunoblotting with antibodies anti-TRDrat and anti-TRDdog. (C) Immunoblotting with 
anti-JCTdog and anti-JCTrat. Molecular weight markers kDa, indicated on the left for each 
immunoblot. 
4.2.2 Early accumulation of expressed JCTdog and TRDdog at juxtanuclear sites  
To visualize the intracellular sites of earliest JCT and TRD accumulation and 
early trafficking, we analyzed cultured adult rat cardiomyocytes after 12, 24, 30 and 48h 
of overexpression.  Confocal images of indirect immunofluorescence were generally 
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acquired as a Z-stack covering the height of the cell in contiguous series of optical 
slices of 0.5 m thickness, allowing us to most clearly determine ER/SR structures 
radiating outward from nuclei. 
Figure 4-2. JCT accumulation at 
juxtanuclear sites Coverslips 
containing cardiomyocytes were 
fixed following no virus (-) or 
treatment with JCT (JCTdog) 
adenovirus for 16, 24, or 30 h, 
and remaining cells harvested for 
immune-blotting. Cells were 
double-labeled with anti-JCTdog 
(green) and anti-JCTrat (red) at 
each time point. Fluorescence 
images for cells were acquired 
using identical settings and 
processed offline at the same 
time, to permit direct 
comparisons. (A) Representative 
cells are shown for time points as 
indicated 16, 24, and 30 h, either 
for JCTdog the green channel (anti-
JCTdog) alone, or merged with red 
JCTrat  (anti-JCTrat). Panel c is the 
same image as shown in b 
following an arbitrary increase in 
the signal offline. Panels f and g 
are the merge images of d and e, RGB channels. Scale bar, 10 µm. (B) Magnification of 
outlined box (panel A-f) showing JCTdog appearing first at juxtanuclear sites. Scale bar 2 
µm. (C) Immunoblot analysis of cardiomyocyte protein extracts showing JCTrat and 
JCTdog levels with increasing times of JCTdog overexpression. Immunoblot was 
performed using anti-JCTrat (detecting both native and expressed forms) and anti-
JCTdog. Molecular weight marker on the left is 31 kDa. 
JCTdog first appeared after 16-24 h of virus treatment, and its early distribution 
showed a restricted pattern of puncta that surrounded nuclei, when viewed in an optical 
plane through the center of a myonuclei.  The most intensely fluorescent puncta were 
those that most closely encircled the nucleus (Figure 4-2 panel A).  Additional puncta of 
lower intensity appeared to radiate away from the nuclear surface along transverse (Z-) 
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lines towards the periphery of the cell.  JCTdog immunofluorescence co-localized with 
that of native JCTrat, validating its passage across, and concentration in, junctional SR.  
With increasing incubation times, JCTdog accumulated at greater distances from the 
nuclear surface, suggesting a peripherally directed movement of protein across the cell.  
By 36-48 h of incubation, the distribution of JCTdog was qualitatively similar to that of 
native JCTrat.  The time course of JCTdog accumulation observed in the microscope was 
validated by immunoblotting of harvested cells (Figure 4-2 panel C) JCTdog levels rose 
significantly between 24 and 48 h, commensurate with the accumulation of fluorescent 
puncta across the cell periphery. 
TRDdog showed a pattern of accumulation that was similar to that of JCTdog.  
TRDdog also first appeared in cultured cardiomyocytes around 16-24 h in culture (Figure 
4-3).  Newly synthesized TRDdog accumulated in cisternae that encircled nuclei at 16 h 
when visualized in optical plane of the nucleus (Figure 4-3 panel A).  TRDdog and TRDrat 
immunofluorescence co-localized and showed a very similar distribution (Figure 4-3 
panels B, C) validating an apparent direct passage of TRDdog across, and concentration 
in, junctional SR.  Thus, a common pathway and time course JCT and TRD 
accumulation across increasingly peripheral junctional SR puncta suggested sites of 
biosynthesis close to the cell surface, with an apparent direct membrane trafficking 
pathway transversely (radially) across junctional SR.  
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Figure 4-3. TRD accumulation at juxtanuclear sites. Coverslips containing 
cardiomyocytes were fixed following treatment with TRD (TRDdog) adenovirus for 16, 24, 
30, or 48 h, and remaining cells harvested for immunoblotting. Cells were double-
labeled with anti-TRDdog (green) and anti-TRDrat (red) at each time point. Fluorescence 
images for cells were acquired using identical settings and processed offline at the 
same time, to permit direct comparisons. (A) Representative cells are shown for time 
points as indicated for anti-TRDdog alone. (B) Immunofluorescence for native TRD (anti-
TRDrat) for the16 h time point, typical for all cells. (C) Magnification of outlined box 
(panel A, 16 h) showing TRDdog appearing first at juxtanuclear sites. Scale bar 2 µm. (D) 
Immunoblot analysis of cardiomyocyte extracts showing TRDdog and TRDrat with 
increasing times of TRDdog overexpression, as indicated. The TRDdog immunoblot was 
counter-stained with anti-TRDrat to show differences in their respective mobilities. 
Molecular weight markers are shown in kDa on the left.  
4.2.3 In situ interaction of JCTdog and TRDdog with CSQ2-DsRed in rough ER 
Although newly-synthesized JCT or TRD formed a punctate pattern by 48 h 
detectable amounts of protein could be observed even closer to the nuclear surface at 
early time points, suggesting that newly formed junctional SR puncta were distal to the 
actual sites of biosynthesis.  
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Figure 4-4. TRD and JCT move along a common pathway to populate junctional SR. 
Cardiomyocytes were not treated 
(-), or co-treated with TRD and 
JCT adenoviruses for 18, 24 or 
48 h, then fixed for 
immunostaining and remaining 
cells harvested for 
immunoblotting. (A) Adult rat 
cardiomyocytes coimmuno-
stained with anti-TRDdog (green) 
and anti-JCTdog (red); nuclei are 
blue. Scale bar, 10 µm. (B) 
Magnification of outlined box 
(panel A). Scale bar, 2 m. (C) 
Upper Stained nitrocellulose 
transfer of protein extracts from 
untreated and treated cells at 
various time points as indicated. 
Lower Autoradiogram from 
immunoblot with anti-TRDdog 
(upper band) and anti-JCTdog 
(lower band) showing canine 
protein expression levels. 
Molecular weight markers are 
indicated on the left.  
To further investigate the sites of junctional SR protein biosynthesis, we 
compared early JCT and TRD sites of accumulation with the bright red DsRed 
fluorescence that accompanies accumulation and concentration of CSQ2-DsRed near 
its site of biosynthesis [85, 171].  Co-expression of either TRD or JCT with CSQ2-
DsRed led to co-localization of their immunofluorescence with CSQ2-DsRed polymers 
in the nuclear envelop (Figure 4-5 panel A).  Prior to formation of CSQ2-DsRed red 
polymers at 24 h, JCT and TRD showed somewhat typical juxtanuclear patterns of 
junctional SR filling.  However, by 48 h, JCT and TRD had accumulated to high levels in 
and around the nuclear envelope, co-localized with CSQ2-DsRed. 
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Figure 4-5. In situ interactions of JCT and TRD with CSQ2-DsRed at juxtanuclear sites. 
Co-expression of CSQ2-DsRed was carried out with either JCT or TRD for 
varying times, as indicated, then cells were fixed for immunostaining and 
remaining cells harvested for immunoblotting. (A) Cardiomyocytes co-expressing 
CSQ2-DsRed and either JCT, TRD, or delTRD, for 24 or 48 h. 
Immunofluorescence staining using either anti-JCTdog or anti-TRDdog is shown 
in green, CSQ2-DsRed is red. Scale bar, 10 mm. (B) Cells were not treated (-) or 
were treated with JCTdog and CSQ2-DsRed adenoviruses for the indicated 
number of hours. Immunoblot data for cells were obtained using a mixture of anti-
CSQ2 and anti-JCTdog antibodies. (C) Cells were not treated, lane 1; treated 
with TRDdog and CSQ2-DsRed adenoviruses for 48 h, lane 2; or were treated 
with delTRD and CSQ2-DsRed adenoviruses for 48 h. Immunoblot data for cells 
were obtained using a mixture of anti-CSQ2 and anti-TRDdog antibodies. A band 
that appears in all lanes near 40 kDa (asterisk, *) was not seen in other 
experiments. 
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Figure 4-6. CSQ2-
DsRed-containing 
ER traffics between 
myonuclei in line 
with MTs. Cardio-
myocytes were 
cultured for 48 h 
with Ad.CSQ2-
DsRed adenovirus, 
and fixed before 
immunostaining with 
anti-alpha tubulin 
(green). (A) CSQ2-
DsRed fluorescence 
shows high levels of 
accumulation in 
juxtanuclear ER 
cisternae, but also 
within longitudinal 
tubules of ER 
extending between 
the two nuclei. (B) 
Double labeling of 
CSQ2-DsRed (red) 
and α-tubulin immune-fluorescence shows abundant MTs extending between nuclei. 
Anti-tubulin immunofluorescence (C) of the panel B inset shows a complex scaffold that 
might support ER tubules containing CSQ2-DsRed (D). Scale bar A, B 10 m and D, 5 
m. 
 
To show that newly made TRD was binding to CSQ2 through its well-
characterized interaction domain [104], we compared the effect of CSQ2-DsRed on 
trafficking of newly accumulated delTRD, a deletion mutant of TRDdog that has absent the 
canonical CSQ2-binding site.  delTRD showed little co-localization or restricted 
anterograde movement with CSQ2-DsRed (Figure 4-5 panel A).  These data suggested 
that CSQ2-DsRed, TRD, and JCT are biosynthesized at a common intracellular site, 
likely corresponding to the nuclear envelope.  These data also demonstrate that both 
JCT and TRD can bind to CSQ2 in situ. 
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Figure 4-7. TRD is retained by 
its in situ binding to 
polymerized CSQ2-DsRed in 
the smooth ER lumen. 
Cardiomyocytes were cultured 
with adenoviruses encoding 
CSQ2-DsRed and TRD for 36-
48 h, which led to co-localized 
protein accumulation around 
and between myonuclei. 
CSQ2-DsRed, once 
polymerization occurs, serves 
as a marker for early ER. (A) 
TRD retained in large part 
within this series of smooth ER 
membranes, depending upon 
the rates of TRD synthesis and 
trafficking. (B, C) Individual 
color channels for CSQ2-
DsRed (red channel) or TRD 
(green channel) are shown in 
black and white (D) At 36 h of 
expression, CSQ2-DsRed was 
present in the nuclear 
envelope, but also present in 
the ER tubules aligned axially across the cell (white lines in inset. TRD puncta (green) 
were aligned along these smooth SR tracts suggesting that smooth ER may contribute 
to sorting of TRD to junctional SR sites (E) Punctate TRD immunofluorescence always 
co-localized with CSQ2-DsRed in nuclear envelope but some portion generally 
appeared to outpace CSQ2-DsRed, leading to green puncta with little CSQ2-DsRed 
fluorescence. Scale bar 10 m, A-C; 5 m, D, E. 
4.2.4 Morphological distinctions between smooth ER and junctional SR 
In this study, we found that longer periods of CSQ2-DsRed accumulation 
produced red fluorescent polymers that populated ER tubules visualized along MTs 
between and surrounding the two myonuclei (Figure 4-6).  This CSQ2-DsRed-positive 
ER often appeared as circular or polygonal tubules, presumably depending upon its 
orientation in optical slices.  Meanwhile, around nuclei, and particularly between nuclei, 
CSQ2-DsRed-containing ER appeared as intertwined tubular and polygonal 
membranes (Figure 4-7 panels B, D).  The underlying MT network in these regions 
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suggested that these more extensive smooth ER components might lie along a dense, 
longitudinally directed and looping MT network. (Figure 4-7 panels B, C).  
To investigate in more detail the ER accumulation sites of CSQ2-DsRed with 
those of newly synthesized TRD and JCT, we examined the CSQ2-binding deletion 
mutant delTRD, to prevent its strong in situ interaction with CSQ2-DsRed.  Generally, 
after 36 h of incubation with the adenovirus, CSQ2-DsRed had developed its red 
polymerization in juxtanuclear cisternae (Figure 4-8 panel A, red fluorescence), during 
which time delTRDdog (Figure 4-8 panel A, green fluorescence) has developed a 
distribution pattern approaching that of native steady-state junctional SR proteins.  
Expressed alone, delTRDdog produced a time-dependent change in fluorescent puncta 
that was similar to that of wild type TRDdog and JCTdog proteins (APPENDIX C Figure A-
2).  When co-expressed with CSQ2-DsRed however, delTRD immunofluorescence and 
DsRed red fluorescence labeled morphologically distinct subcompartments (Figure 4-8 
panels B, C).  CSQ2-DsRed was localized to the nuclear envelope and smooth 
longitudinal ER tubules aligned between and around nuclei along MT-like pathways.  
However, delTRD immunofluorescence was generally very low in CSQ2-DsRed-
containing smooth ER, instead concentrating in puncta.  Longer incubation times (~72 
h) led to increased fluorescence intensity of juxtanuclear tubules of CSQ2-DsRed, yet 
junctional SR sites marked by delTRD immunofluorescence still maintained a distinct 
separation from DsRed fluorescence.  
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Figure 4-8. The CSQ2-
binding mutant delTRD 
readily crosses the smooth 
ER to concentrate at sites 
of junctional SR. 
Cardiomyocytes were 
cultured with adenoviruses 
encoding CSQ2-DsRed and 
TRD for 48 h. (A) CSQ2-
DsRed fluorescence 
surrounds each myonuclei, 
but little overlap is seen 
with green anti-TRD 
immunofluorescence 
(delTRD). (B-B2 and C-C2) 
Enlarged portions of the two 
perinuclear regions (insets 
panel A) are shown with the 
individual channels for 
CSQ2-DsRed and delTRD. 
CSQ2-DsRed was highly 
enriched in areas around 
and between nuclei, and 
greatly reduced in more 
distal ER/SR compartments 
(panels B1 and C1). TRD 
immunofluorescence 
(panels B2 and C2) shows 
the opposite effect: reduced 
immunofluorescence in 
CSQ2-DsRed compartments (smooth ER), with concentrated junctional SR puncta 
originating in tubules outside of the perimeter of ER defined by CSQ2-DsRed. Transition 
of smooth ER-to-junctional SR (arrows) (D) TRD after 36 h overexpression can be seen 
traversing the smooth ER as it traffics toward junctional SR enrichment (E) After 48 h, 
the smooth ER becomes expanded by CSQ2-DsRed at the same time as junctional SR 
puncta appear at further distances from the nuclear surface.   
Transitions from the more longitudinally oriented CSQ2-DsRed-positive ER, to 
transversely aligned puncta containing delTRDdog immunofluorescence, generally 
occurred over a radial distance of only a few hundred nanometers.  This indicated that 
delTRD was retained at lower levels in the proximal CSQ2-DsRed that did not develop 
into fluorescent puncta.  Beyond a defined distance from the central axis of the cell, 
67 
	
delTRD began showing punctate junctional SR sites along the MTs, taking on the 
punctate appearance of junctional SR (Figure 4-8 panel D).  The fundamental difference 
between smooth ER-filled tubules and the more distal junctional SR puncta appeared 
therefore to correspond to whether a deposition and concentration of ER cargo (TRD 
and JCT) occurred in the vicinity of the Z-line.  Since TRD and JCT readily sort and 
traffic to junctional SR, and polymerized (red) CSQ2-DsRed concentrates almost 
exclusively in a more proximal ER subcompartment that extends away from 
juxtanuclear rough ER, we propose that the CSQ2-DsRed is a unique marker of a pre-
junctional SR (cardiac rough ER and cardiac smooth ER).  
4.2.5 Inhibition of anterograde trafficking by nocodazole 
Trafficking of JCT and TRD away from the nuclear envelope occurs within ER 
tubules that are known to be associated with MTs, along longitudinal and transverse 
pathways, we predict that trafficking to junctional SR would require a MT platform from 
which molecular motors could carry the junctional SR cargo. 
To determine the effects of MT disruption on early accumulation and initial 
trafficking steps of JCT and TRD, we used nocodazole.  Effects of nocodazole on 
disruption of junctional SR have been previously reported [188].  Immunofluorescence 
of both α-tubulin and β-tubulin was examined in the adult rat cardiomyocyte, and 
differences have been reported in the monomer distribution as shown (Figure 4-9).  
Using each of two different anti-tubulin antibodies, a high degree of MT disruption was 
seen after as little as 2 h incubation with 20 M nocodazole (Appendix C Figure A-3). 
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Figure 4-9. Nocodazole disrupts 
anterograde movement of 
junctional SR proteins. Immuno-
fluorescence performed on adult 
rat cardiomyocytes untreated (-) 
or treated (+) with nocodazole 
(20 M). Cells were fixed and 
stained after 48 h in culture. (A) 
Cardiomyocytes treated with 
Ad.TRDdog and stained with anti-
TRDdog (green). Cardiomyocytes 
treated with Ad.JCTdog and 
stained with anti-JCTdog (green). 
Cardiomyocytes co-treated with 
Ad.TRDdog and Ad.JCTdog and 
stained with anti-TRDdog (green) 
and anti-JCTdog  (red) (B) 
Magnification of outlined box 
from panel B showing TRDdog. 
(C) Immunocytochemistry on 
cardiomyocytes showing α-
tubulin (green) and β-tubulin 
(red). Scale Bar 10 m in A, C, 2 
m in B.  
 
Although MT structure was overtly disrupted by 2 h of 20 µM nocodazole, 
changes in the overall patterns of JCT and TRD puncta were not obvious at the light 
microscope level (Appendix C Figure A-3).  Therefore, to ascertain the effects of MT 
disruption on JCT and TRD trafficking, we examined whether nocodazole would alter 
the sites of protein accumulation over the entire period of time during which JCT and 
TRD would acquire their normal junctional SR distribution.  Nocodazole was therefore 
added to cells after only 16 h in culture.  Such extended periods of MT disruption largely 
prevented JCT and TRD from leaving their sites of synthesis.  These treatments 
resulted in bright fluorescent rings of juxtanuclear ER clusters as opposed to the 
anterograde trafficking seen in untreated cardiomyocytes (Figure 4-9 panel B).  Levels 
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of JCT (Appendix C Figure A-3 panel C) and TRD (data not shown) remained similar in 
nocodazole treated and untreated cells.  The data suggested that the disruption was 
mostly affecting the transport of newly synthesized proteins and not their steady state 
distributions. 
4.3 Summary  
In this chapter, we showed how junctional SR protein biogenesis begins in the 
nuclear envelope using immunofluorescence analyses of protein expression.  Newly 
synthesized JCT and TRD appeared by 24 h as bright fluorescent puncta close to the 
nuclear surface, decreasing in intensity with increasing radial distance.  With increasing 
time (24-48 h), fluorescent puncta appeared at further distances from the nuclear 
surface, resembling steady-state patterns of junctional SR.  CSQ2-DsRed prevented 
anterograde traffic of newly made TRD and JCT.  In situ binding of TRD to CSQ2-
DsRed and effects on its trafficking were abolished if a form of TRD was used in which 
CSQ2-binding sites are removed (delTRD).  
Double labeling studies confirmed that delTRD first concentrates in junctional SR 
puncta that are morphologically distinct from CSQ2-DsRed sites, although delTRD also 
accumulated at low levels in these earlier secretory subcompartments.  Besides being 
localized to the nuclear envelope (rough ER), CSQ2-DsRed labeled a novel smooth ER 
network that surrounds nuclei and connects the nuclear axes.  
The transmembrane junctional SR proteins transit across perinuclear smooth ER 
that extend along microtubules away from the nucleus, concentrating only where ER 
trafficking crosses Z-lines.  ER/SR protein traffic required MTs, as nocodazole treatment 
led to disruption and minimal anterograde protein movement of both JCT and TRD, with 
accumulations close to the nuclear envelope.  
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CHAPTER 5 
TRAFFICKING OF THE LUMINAL SR PROTEIN CSQ2 
5.1 Rationale  
The luminal junctional SR protein CSQ2 was discovered many years prior to the 
transmembrane CSQ2-binding proteins JCT and TRD (Chapter 4), and in many ways is 
the most enigmatic of the group of proteins classically known to enrich in junctional SR 
subcompartments.  As a luminal protein, it is not restricted by the dynamics of the lipid 
bilayer, and should be capable of faster trafficking through secretory pathway lumens.  
At the same time, because it contains no known retrieval sequences, it should in 
principle be secreted from the cardiomyocyte - but apparently is not.  We have shown 
that the retention of different forms of the protein CSQ (e.g. CSQ1, CSQ2, and CSQ2-
DsRed) is uniquely determined by their polymerization, which is sensitive to levels of 
Ca2+ and ionic milieu [19]. 
ER trafficking of luminal cargo requires communication with cytosolic trafficking 
proteins.  To define the biosynthetic trafficking pathway for luminal junctional SR 
proteins, we expressed canine CSQ2 and detected it with canine-specific protein 
antibodies.  These studies extend the data obtained for JCT and TRD, and present a 
wider view of junctional SR protein trafficking and junctional SR compartmentation. 
Hypothesis: CSQ2, a luminal junctional SR protein is synthesized in the juxtanuclear 
rough ER and traffics through the same ER/SR pathways defined by our studies on the 
transmembrane proteins JCT and TRD.   
5.2 Results 
5.2.1 Detection of CSQ2dog using species-specific antibodies 
To determine the specificity of the antibody utilized in the detection of expressed 
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canine CSQ2, immunoblot analysis was performed on protein samples from canine and 
rat microsomal vesicles.  In comparison to canine microsomes where CSQ2 was 
detected, no band was detected in rat microsomes using anti-CSQ2dog antibody (Figure 
5-1 panel B).  Thus, this data shows that the antibody used for detection of CSQ2 is 
highly specific to the expressed canine form with relatively no cross reactivity with the 
rat form of the protein.  Meanwhile, rat forms of CSQ2 can be detected using a second 
antibody that reacts with both canine and rat forms. 
When immunocytochemistry was performed on adult rat cardiomyocytes 
expressing CSQ2 for 48 h, CSQ2dog co-localized with the endogenous native rat form of 
the protein at junctional SR sites and displayed a similar subcellular distribution (Figure 
5-1 panel C).  However, displayed a similar but antibody specific staining. 
Figure 5-1. Specificity of anti-CSQ2 
antibodies. Samples (50 g) of 
canine heart microsomes (MVc) and 
rat heart microsomes (MVr) were 
analyzed by SDS-PAGE (10% 
acrylamide) and transferred to 
nitrocellulose. (A) Amido black 
stained nitrocellulose. (B) Immuno-
blotting of CSQ2 (arrowhead) using 
anti-CSQ2dog and anti-CSQ2rat 
antibodies. (C) Immunofluorescence 
of CSQ2 in cultured adult rat 
cardiomyocytes treated with 
Ad.CSQ2 for 48 h using anti-CSQ2 
(green) and anti-CSQ2rat (red). Scale 
Bar 10 m.  
 
 
 
5.2.2 Determination of CSQ2 initial sites of accumulation  
 
To determine the biosynthetic pathway luminal junctional SR proteins follow, a 
time course of canine CSQ2 expression was performed over 48 h in adult rat 
C	
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cardiomyocytes.  To visualize the CSQ2 accumulation, cultured rat adult 
cardiomyocytes were analyzed after 16, 24, 30 and 48h of overexpression.  Confocal 
images of indirect immunofluorescence were generally acquired as a Z-stack covering 
the height of the cell in contiguous series of optical slices of 0.5 m thickness.  
In contrast to accumulation at juxtanuclear sites for the transmembrane junctional 
SR proteins TRD and JCT, CSQ2 was widely distributed throughout the cell after only 
16 h, accumulating at junctional SR sites with no concentration around the nucleus 
(Figure 5-2).  We believe that the rapid transit and approach to steady state distribution 
reflects the differences between the transport of luminal and transmembrane ER/SR 
proteins.  Thus far, these data do not support our hypothesis that all junctional SR 
proteins are made in a common juxtanuclear sites 
Also, unlike the distinct juxtanuclear localization of the fusion protein CSQ2-
DsRed (see Chapter 4 section 4.2.2), CSQ2 (wild-type) was widely distributed.  The 
differences in localization for wild-type versus CSQ2-DsRed likely reflect their 
polymerization-dependent localizations.  This would explain why CSQ2-DsRed remains 
in rough ER while native CSQ2 traffics more distally to contiguous junctional SR sites. 
Given the rapid transit of CSQ2 across ER /SR compartments, we hypothesized 
that the luminal protein trafficking was too rapid to permit juxtanuclear accumulation.  
Therefore, to visualize the earliest sites of CSQ2 accumulation, overexpression of 
CSQ2 was performed at higher adenoviral concentrations 2x and 5x. 
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Figure 5-2. Time course of CSQ2 accumulation at junctional SR sites. Coverslips 
containing cardiomyocytes were removed and fixed following treatment with Ad.CSQ2 
for 16, 24, 30 and 48 h and remaining cells harvested for immunoblotting. (A-D) 
Immunofluorescence of CSQ2 (green) and nuclei (blue) at different time points, cells 
were stained with anti-CSQ2dog. Scale bar 10µm. (E) Amido Black stained nitrocellulose 
of protein extracts from cardiomyocytes corresponding to 16, 24, 30 and 48 h of 
Ad.CSQ2 treatment. (F) Immunoblot analysis of cardiomyocyte protein extracts using 
anti-CSQ2 showing CSQ2 levels with increasing times of canine CSQ2 overexpression. 
Molecular weight markers (kDa) indicated on the left. 
In contrast to CSQ2 1x adenoviral treatments, higher juxtanuclear CSQ2 
immunofluorescence signals were detected in cardiomyocytes that received 2x and 5x 
Ad.CSQ2 (Figure 5-3).  The distribution of CSQ2 fluorescence at 5x Ad.CSQ2 
treatments displayed a membrane-subcompartment-filled in juxtanuclear membrane 
sites and not a strictly punctate pattern as seen at distal sites.  These data support the 
idea that CSQ2 is also synthesized in and around the nuclear envelope, although the 
levels of overexpression needed to visualize it are too high to warrant detailed analysis.  
Interestingly, the changes in ER morphology that accompanied the highest levels of 
CSQ2 overexpression in the juxtanuclear area appear somewhat similar to the 
increased ER cisterna observed with CSQ2-DsRed expression (Chapter 4 section 
4.2.4).  
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Figure 5-3. Higher rates of CSQ2 biosynthesis create higher fluorescence intensities at 
juxtanuclear sites. Coverslips containing cardiomyocytes were removed and fixed 
following treatment with Ad.CSQ2 for 48 h at 1x, 2x and 5x, remaining cells were 
harvested for immunoblotting (A) Immunofluorescence of CSQ2 (green) in adult rat 
cardiomyocytes detected using anti-canine CSQ2, following 1x, 2x and 5x Ad.CSQ2 
treatments for 48 h. Nuclei (blue) are stained with DAPI. Scale bar 10m (B) Enlarged 
portions of the perinuclear regions (panel A, insets) (C) Autoradiogram showing CSQ2 
levels. Protein extracts are from cardiomyocytes cultured for 48 h either untreated or 
treated with Ad.CSQ2-WT at 2x and 5x, respectively. Molecular weight markers in kDa 
indicated on the left. (D) Fluorescence intensity of CSQ2. Quantification of fluorescence 
from CSQ2dog expression (in 10 cells /condition) was measured as a function of 
transverse distance (m) from the nuclear edge in 48 h cultured cardiomyocytes. Values 
of fluorescence intensity are relative to the intensity at the edge of the cell. 	
5.2.3 In situ interaction of TRDdog with CSQ2  
Previous studies have demonstrated in vitro interaction between proteins that are 
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part of the Ca2+ release complex.  Moreover, we have shown here that CSQ2-DsRed 
expression led to the complete retention of TRD and JCT in and around the nuclear 
envelope.  We therefore, sought to determine whether CSQ2 accumulation, localization 
and rates of trafficking would be affected by the overexpression of TRD or vice versa.  
Primary adult rat cardiomyocytes were co-treated with Ad encoding canine CSQ2 and 
TRD.  Expressed protein levels were detected using canine specific anti-CSQ2 and anti-
TRD, immunoblotting showed an increase in protein levels at 48 h compared to 24 h 
(Figure 5-4, panel A).  Immunocytochemistry showed no accumulation of CSQ2 at 
juxtanuclear sites upon co-overexpression with TRD (Figure 5-4, panels B, C), unlike 
CSQ2-DsRed co-overexpression that concentrated TRD at juxtanuclear rough ER sites.  
The slower trafficking transmembrane TRD did not exhibit an overt effect on the faster 
trafficking of luminal CSQ2.  This may be due to the rapid passage and dispersal of 
CSQ2 through the SR/ER lumen away from the membrane surface and the nuclear 
envelope. 
5.2.4 Effect of nocodazole on junctional SR sites and CSQ2 trafficking  
MTs are known to interact with the ER and are involved in the extension of ER 
tubules.  To determine the effect of nocodazole on CSQ2 accumulation at junctional SR 
sites, cells expressing both CSQ2dog and TRDdog were treated with 20 M nocodazole 
(Figure 5-4, panel D).  Immunofluorescence analysis showed a distinct effect on the 
transmembrane protein TRDdog but with minimal to no effect on the expressed luminal 
protein CSQ2.  Nocodazole also had no effect on endogenous junctional SR containing 
CSQ2 localization upon nocodazole treatment (Appendix C Figure A-4).  The lack of 
effect of nocodazole on CSQ2 trafficking or native junctional SR puncta compared to 
TRD anterograde trafficking may be due to the presence of multiple cytoskeletal 
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structures that help to maintain the more distal subcellular membrane compartments 
[127]. 
Figure 5-4. CSQ2 maintained independent transit when co-expressed with TRD and 
was not similarly disrupted by nocodazole treatment. Coverslips containing 
cardiomyocytes were removed and fixed following culture for 24 or 48 h and co-treated 
with both Ad.CSQ2, Ad.TRD and with or without nocodazole, remaining cells were 
harvested for immunoblotting (A) Autoradiogram showing protein levels of expressed 
CSQ2 and TRD. Protein extracts were obtained from cardiomyocytes co-treated with 
Ad.CSQ2 and Ad.TRD for 24 and 48 h. Proteins detected using anti-CSQ2dog, and anti-
TRDdog.  Molecular weight markers (kDa) indicated on the left. (B-D) 
Immunofluorescence of CSQ2 (green) and TRD (red) in cardiomyocytes co-treated with 
Ad.CSQ2 and Ad.TRD for 24 h or 48 h. (B) Cultured for 24 h, (C) Cultured for 48 h (D) 
cultured for 48 h and treated with nocodazole (20 µM). Nuclei (blue) are counter-stained 
with DAPI. Scale bar 10 m.  
5.3 Summary 
In this study, we examined the luminal SR protein CSQ2 biogenesis.  CSQ2 
established steady state distribution and did not show juxtanuclear accumulation at 1x 
CSQ2dog expression.  Sites of biosynthesis were less prominent for CSQ2 because it is 
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luminal (compared to TRD or JCT), and the wild-type forms of CSQ2 cannot polymerize 
in the juxtanuclear compartment.  Nevertheless, higher CSQ2 expression levels were 
able to validate the hypothesis that junctional SR proteins have a common 
biosynthetic/secretory pathway.  The data provides a consistent model of ER and SR 
transmembrane (Chapter 4) and luminal (Chapter 5) protein transport across the 
cardiomyocytes, and a new understanding of pathways by which cellular Ca2+ handling 
protein complexes can be maintained and modified. 
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CHAPTER 6 
DISCUSSION 
Crucial distribution and localization of proteins within the adult cardiomyocyte 
inner membrane system are the result of the ongoing sorting and trafficking of proteins.  
Many resident proteins of the ER/SR and sarcolemmal membranes continually take part 
in this membrane protein traffic, yet very little is known about these processes in the 
heart.  A range of biochemical and immunological techniques were used in this 
Dissertation to develop a basic model of protein trafficking in the cardiomyocyte that 
may also explain fundamental changes observed in intact hearts during failure.  
6.1 CSQ2 mass redistribution in two types of cardiomyopathies 
In Chapter 3, we evaluated CSQ2 purified from heart tissue following two 
different types of induced cardiomyopathies.  Remarkably, we found similar patterns of 
mass redistribution in the two disparate types of cardiomyopathies when compared to C 
mongrel dogs.  The changes in mongrel dogs mimicked the changes previously 
reported for tachypaced beagles [178], with a series of interesting new findings.  
Overall, our results suggest that a common mechanism for change in CSQ2 mass 
(glycosylation and phosphorylation) and turnover exists that is independent of the 
pathologies that lead to the syndrome of HF (Figure 3-1 panel b), likely reflecting an 
adaptive response of the distressed myocardium.  These studies involved changes in 
two cardiac pathological mechanisms by which an animal is put into heart failure, 
apparently manifested through a common biochemical and cell biological change. 
Hearts from HFi dogs reportedly exhibit increased LV wall thickening (27%) and 
increased heart weight to body weight ratios (18%) [165], whereas tachypacing is 
marked by LV wall thinning, LV dilatation, and reduced heart weight [184].  HFt hearts 
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can develop LV hypertrophy following resumption of normal pacing [189], suggesting 
that a single program of remodeling develops that is independent of the induction route.  
On the other hand, the different types of hypertrophy reported for HFt and HFi tissues 
might explain the similar but distinct changes in CSQ2 mannose trimminig reported 
here. 
The single biological change might be related to changes known to occur as part 
of cardiac hypertrophy.  Mechanisms for cardiac hypertrophy remain unclear but are 
likely to involve formation of new Ca2+ microdomains within the ER or SR of the inner 
membranes of the cardiomyocyte [112, 190].  Changes in CSQ2 glycan structure in 
failed heart tissue correspond to changes brought about by the formation of new protein 
that undergoes less glycan processing. 
CSQ2 molecules in the canine heart undergo co-translational N-linked 
glycosylation on 316Asn [167].  In addition, canine CSQ2 molecules are phosphorylated 
on 0,1,2, or 3 serines contained within the CSQ2-specific C-terminal cluster 378,382,386Ser 
[167, 191].  This modification is thought to be carried out by a cytosolic protein kinase 
CK2, also occurring co-translationally [183].  Therefore, the greatest posttranslational 
mass for CSQ2 is 47,478 Da, which contains 9 mannoses and 3 phosphates.  This form 
of CSQ2 ordinarily only accumulates at high relative levels when canine cDNA is 
adenovirally-overexpressed in non muscle cell lines [167].  In contrast, very little of this 
unprocessed form is found in the mammalian heart [167, 179].  Most CSQ2 in the heart 
is highly mannose-trimmed and relatively dephosphorylated [179].  We believe that he 
degree of posttranslational processing is likely to reflect critical regulatory roles in CSQ2 
turnover.  Mannose trimming of N-linked glycans is likely to reflect CSQ2 degradation 
[180, 181], whereas CK2 phosphorylation states may reflect CSQ2 turnover [179, 183].  
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The mechanisms underlying the CSQ2 mass redistribution are likely to lie in 
CSQ2 cellular processing, from its biosynthesis, to its accumulation in ER/SR 
subcompartments, to its degradation.  One possibility for the changes is that the two 
accumulated pools emanate from two distinct sites of CSQ2 biosynthesis (rough ER), 
one that is roughly common to both normal and HF myocardium (Pool I), and one that is 
activated only in cardiomyopathy states of the myocardium (Pool II).  The lack of 
posttranslational processing of Pool II suggests either that this CSQ2 is not being 
transported to junctional SR, or perhaps degrades before undergoing further mannose 
trimming.  In studies aimed at elucidating sites for junctional SR protein synthesis 
(Chapter 4 and 5), we found no evidence to support more than a single subcellular site.  
We cannot however, exclude the possibility that additional sites of biosynthesis arise or 
become activated in cardiomyopathy.  
An immunofluorescence analyses of thin tissue sections was aimed at 
determining whether quantifiable differences could be detected across the cell, from 
juxtanuclear rough ER transversely to the cell surface.  The lack of significant changes 
in CSQ2 immunoreactivity in C and HF tissue may suggest that a more complex 
subcellular distribution underlies the observed mass redistribution.  In our new 
trafficking model, CSQ2 and other SR proteins could exhibit differences in a smooth ER 
to junctional SR step that could also explain the changes in its glycan structure.  It will 
be interesting to extend the immunofluorescence analyses to include changes that are 
reflective of MT trafficking or smooth ER transport; new ideas that based upon our 
proposed model of membrane protein trafficking.  
The two CSQ2 mass pools could also develop from a single site of CSQ2 
biosynthesis, after which differences occur in the rates of anterograde trafficking.  
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Different rates of anterograde transit through the cardiac secretory pathway might result 
from different rates of CSQ2 translocation through CK2-modified translocons [183, 192, 
193], or as a result of increased retention of CSQ2 transcripts in rough ER following 
CK2 phosphorylation [183].  We previously reported that CSQ2 in the failing beagle 
heart showed increased phosphorylation on protein kinase CK2-sensitive sites [178], 
and we have also shown that CK2 phosphorylation of CSQ2 can result in increased ER 
retention [183].  Calnexin, another resident ER/SR protein substrate for CK2, may 
associate with the translocon upon CK2 phosphorylation [193].  A broader role for CK2 
activation of cardiac hypertrophy was recently predicted, based upon a hypertrophic 
activation of p27/Kip1, which leads to CK2 dissociation and activation [194].  This model 
of cardiac hypertrophy involves the intriguing connection between p27/Kip1 activation of 
cell proliferation (GS-phase transition) in dividing cells, and activation of hypertrophy 
in the non-dividing cardiomyocyte.  
Finally, accumulation of CSQ2 in a second metabolic pool might represent the 
effects of T-tubule changes.  Loss of normal T-tubule morphology has been widely 
reported in HF based upon microscopic visualization in tissue and cultured cells of 
mammalian HF models [195-197].  Retraction of the transverse invaginations of 
sarcolemma leaves a disorganized ultrastructure with orphaned RyRs that contribute to 
arrhythmogenesis through under-regulated sparks [195].  With loss of triggered Ca2+ 
release, CSQ2 might play a more prominent role in regulation of SR Ca2+ release in 
RYRs orphaned by T-tubular reorganization.  Junctophilin-2, a junctional SR protein that 
forms a critical connection to T-tubules, is thought to play a role in T-tubule 
reorganization [198].  How and whether such changes would affect other junctional SR 
proteins or CSQ2 processing is not known.  Data reported here would represent the first 
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evidence for specific changes in junctional SR protein processing with T-tubular change 
in vivo.  
6.2 Junctional SR subdomains: protein trafficking and accumulation 
In the studies described in Chapter 4 and 5, we overexpressed JCT, TRD and 
CSQ2 in cultured adult rat cardiomyocytes.  A putative transport pathway that would 
populate successive junctional SR subcompartments has not been previously 
described, primarily because little attention has been given to the specialized cell 
biology of the cardiomyocyte.  In these studies, we were able to show evidence for 
synthesis in and around the nuclear envelope.  In addition, we established CSQ2-
DsRed as a marker for a novel compartment based upon double labeling with either 
TRD or delTRD.  
Studies of SR subcompartment biogenesis have mostly examined the change in 
subcompartmentation during muscle cell differentiation, and while those studies can 
provide insights, they are not aimed at the fundamental questions of cardiac SR biology 
of the adult cardiomyocyte.  In our studies we specifically studied primary adult 
cardiomyocytes.  Newly synthesized TRD and JCT generated immunofluorescent 
puncta close to the nuclear surface 18-24 h post-adenoviral expression, as did CSQ2 
but only at accelerated rates of synthesis.  Data obtained for TRD, JCT and CSQ2 
corroborate previous findings of CSQ2-DsRed synthesis within cisternae that surround 
myonuclei, generating a model of common trafficking for all junctional SR proteins.  
In situ interactions between TRD or JCT and CSQ2-DsRed, and effects of 
nocodazole on trafficking, suggested that a smooth ER likely underlies all membrane 
protein trafficking radially and axially away from the nuclear envelope, maintaining 
junctional SR protein levels through selective retention.  ER transmembrane protein 
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traffic requires intact MTs, as nocodazole treatment led to loss of anterograde JCT and 
TRD traffic away from the nuclear envelope.  Disassembly of MTs prevented 
anterograde trafficking, leading to build-up of protein in the nuclear envelope as 
predicted by our general model. 
Given that CSQ2-DsRed maintains ability for rapid in situ Ca2+-binding and 
release around the nucleus [171], we reasoned that the fusion protein CSQ2-DsRed 
might affect its well-established in vitro binding partners TRD and JCT.  Indeed, rough 
ER-localized CSQ-DsRed was able to form a veritable net that prevented anterograde 
trafficking of JCT and TRD.  Upon co-expression of CSQ2-DsRed with TRD and/or JCT, 
anterograde trafficking to junctional SR was completely inhibited, and JCT and TRD 
were retained within the nuclear envelope and juxtanuclear membranes.  Under these 
conditions, JCT and TRD did not show the punctate staining of junctional SR, but 
collected to a high level in juxtanuclear cisternae characteristic of CSQ2-DsRed and the 
rough ER.  Lack of CSQ2-DsRed binding to delTRDdog, prevented retention of TRD in the 
nuclear envelope, but did not alter its concentration in junctional SR puncta, suggesting 
that the KEKE-motif that binds CSQ2 in vitro [104] in TRD (and presumably JCT) is not 
necessary for its targeting and concentration in junctional SR.  Wild-type CSQ2, 
however, was not retained by the slower-trafficking TRD.  Since in situ interactions were 
shown to be able to occur, the lack of interaction between newly made transmembrane 
TRD and the newly made luminal CSQ show how protein interactions within the 
secretory pathway require some spatial coordination, a situation that must occur in vivo.  
The amount of time needed for TRD and JCT to accumulate to levels sufficient 
for confocal imaging (12-16 h), and the time intervals of ~12 h needed for seeing 
changes in protein localization indicative of its trafficking, reflect the passage through 
84 
	
the lipid bilayer and across longitudinal tubules of ER. JCTdog and TRDdog 
immunofluorescence traverses the nuclear envelope (rough ER) with little retention, yet 
areas of concentrated protein can be seen in the nuclear envelope, which appear to 
represent an initial sorting step from which transit is launched.  Visualization of JCTdog 
or TRDdog within the nuclear envelope required binding it to the CSQ2-DsRed polymer 
that never leaves the ER, or addition of nocodazole to disassemble its anterograde 
escape route.  
An alternative explanation for the observed time-dependence in accumulation is 
a rate-limiting mRNA transport step.  In such a model of our data, RNA would have 
been transcribed and spliced close to the nuclear surface; mRNA would then be 
transported along MTs aligned along Z-lines.  In this paradigm, protein synthesis would 
presumably occur at successive junctional SR puncta over 48 h.  Metsikko and co-
workers hypothesized a specialized mechanism for “Ca2+-handling” proteins in cultured 
skeletal muscle myotubes.  They described a subcellular localization for CSQ1 and 
SERCA mRNA using electron microscopic in situ hybridization [199].  However, the 
differential binding of TRDdog and delTRDdog to perinuclear CSQ2-DsRed, indicate that 
the rate of TRD accumulation across the cell interior is dependent upon anterograde 
protein traffic instead of a putative cytosolic mRNA transport. 
Smooth extensions of the rough ER membrane traffic proteins away from the 
nucleus along microtubules radially along Z-lines, as well as longitudinally (axially).  The 
data suggest that retention of junctional SR cargo proteins near T-tubules occurs via 
this ER traffic.  ER tubule extension may occur in response to MT polymerization 
through attachment of ER to MT tips.  Membrane trafficking and organization has been 
linked to microtubule organization [146, 200].  MTs and the molecular motors dynein 
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and kinesin are thought to regulate the dynamic changes that are part of steady-state 
SR biology [188].  The most common mechanism for MT-based transport is through 
cargo association either directly or indirectly with motor proteins [201].  We hypothesize 
that following protein maturation in juxtanuclear rough ER cisternae, ER tubules or 
vesicles containing transmembrane JCT and/or TRD traffic towards Z-lines along MTs 
(Figure 4-9).  Here we showed that upon 36 h treatment with the MT disrupting agent 
nocodazole, newly synthesized TRD and JCT failed to traffic beyond the nuclear 
envelope, so that newly made JCT and TRD failed to develop and populate 
characteristic junctional SR puncta.  This disruption of junctional SR population 
suggests that a critical MT motor-associated transport is essential for delivery of these 
newly synthesized proteins to the junctional SR sites.   
Vega et al examined motile SR boutons in the SR of adult ventricular myocytes 
labeled by Ad overexpression of red fluorescent protein fused to the well-known ER-
retrieval tetrapeptide (RFP-KDEL) [188] (-KDEL ER retrieval discussed in Chapter 1, 
section 1.4.4).  Their data show that RFP-KDEL fluorescence labels the nuclear 
envelope to high levels, and along transverse membranes.  Live cell imaging of motile 
(corbular) SR boutons in the cell periphery that contain RyR showed longitudinal 
movements across Z-line boundaries over the course of several minutes, providing 
evidence of longitudinal trafficking once junctional SR proteins have populated sites in 
the cell periphery.  Although longitudinal trafficking was not explicitly measured in our 
experimental system, such protein movements were inferred from the double labeling 
studies carried out with CSQ2-DsRed and TRD/delTRD.  Because the ER exit site 
marker sec23 is enriched in a similar Z-line pattern in these cells [85] we previously 
suggested that longitudinal traffic away form Z-lines might represent a cardiac ERGIC.  
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The current studies offer important additional insights into this question.  We showed 
here that CSQ2-DsRed remains associated with ER tubules that remain distinct from 
junctional SR for at least the 48 h that we recorded its location (this distinction extended 
to at least 72 h, N. Sleiman and S. Cala, unpublished observations).  The mechanism of 
smooth ER to junctional SR transition (Chapter 4 Figure 4-8) remains unknown, but 
would be consistent with a role of ER exit sites and the reported build-up of sec23 
immunofluorescence along Z-lines [85].   
Protein synthesis is a prerequisite for cardiomyocyte health, but accelerated 
protein synthesis is a marker of cardiac hypertrophic growth. In cardiomyocytes, the SR 
plays an important role in contractile Ca2+ handling compared to other cell types, and 
therefore is more extensive and complex.  In Chapter 4, we observed an apparent 
proliferation of ER following CSQ2-DsRed overexpression.  These juxtanuclear 
junctional SR sites might play a role in the maintenance of cardiac hypertrophy.  The 
distance (roughly 1 m) from the nuclear edge is theoretically close enough to serve as 
the Ca2+ microdomain hypothesized to support nuclear transcription associated with the 
hypertrophic state [66, 190].  In support of this idea, we previously reported that the 
Ca2+ that is bound to CSQ2-DsRed in adult cardiomyocytes is sufficient to elicit 
localized perinuclear Ca2+ transients, and in neonatal cardiomyocytes is sufficient to 
cause hypertrophic growth determined as increased surface area [171].  Thus, these 
juxtanuclear rough ER cisternae and tubules might play a role as a localized Ca2+ 
microdomain to support Ca2+-dependent transcription thought to drive cardiomyopathic 
forms of hypertrophy. 
6.3 Model of the inner membrane system in the adult cardiomyocyte 
Based upon our extensive fluorescence microscopy data using the unique ER 
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and SR markers developed in our studies, we propose an overall model of protein 
trafficking to junctional SR.  The protein markers reflect a series of inner membrane 
subcompartments and their cell biological relationships. The most important elements of 
our proposed model are as follows: 
1. Junctional SR proteins are synthesized in the nuclear envelope, generally in both 
nuclei. 
2. Rough ER is connected to an extensive and plastic smooth ER that connects the 
two perinuclear regions.  This smooth ER is comprised of polygonal tubules 
between the nuclei, but also includes extensive tubules or cisternae that align 
longitudinally. 
3. Population of junctional SR subcompartments arises from longitudinally aligned 
smooth ER that circumvents the cell but is also prominently filled via transversely- 
aligned membranes. 
4. Smooth ER appears to expand with increasing levels of CSQ2-DsRed expression, 
and in so doing, shifts junctional SR subcompartments to more peripheral areas of 
the cell. 
Proteins destined for inclusion into membrane structures are synthesized on 
membrane bound ribosomes (rough ER).  Critical processes known to occur in rough 
ER include signal sequence docking, mRNA translation, protein translocation into the 
ER, N-linked glycosylation, and folding.  In the adult cardiomyocyte, the predominant 
site of junctional SR protein biosynthesis occurs in close proximity to the nucleus, 
presumably within the nuclear envelope.  Smooth ER can be comprised of tubules and 
flattened cisternae that are free of ribosomes.  
Sorting of newly-synthesized proteins to their final destinations requires elaborate 
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specializations of the ER such as transitional ER and Golgi.  Transitional ER is a major 
ER subcompartment, free of ribosomes.  Along smooth ER, transitional ER forms sites 
of ER exit, from where an ERGIC can form comprised of fused ER-Golgi transport 
vesicles and tubules.  In cardiomyocytes, the cytoskeletal scaffold is involved in the 
proper localization of proteins (e.g. ion channels) to specific domains of the 
sarcolemma.  The proper expression of ion channels in the heart is charted by 
cytoskeletal components specifically, MTs.  Not much is known of how these cargo are 
elected and targeted.  The extent of MTs involvement and disruption in the localization 
or delivery of transmembrane junctional SR was dramatic.  To improve the 
understanding of cardiac protein synthesis and trafficking and thus the remodeling that 
accompanies cardiomyopathies that we consider involves this subcellular remodeling of 
intracellular membranes.  
 
Figure 6-1. Schematic model of junctional SR filling by newly-made junctional SR 
proteins. In adult cardiomyocytes (Normal), protein translation into rough ER 
membranes occurs in or near the nuclear envelope (NE). Areas exist within the NE 
(green ellipses) in which translocon complexes undergo alignment with sarcomeres to 
transport jSR proteins radially (vertical blue arrows). Rough ER becomes sheets or 
tubules of smooth ER (curved and longitudinal turquoise arrows) that, along with Z-
tubules, promote an axial filling of jSR puncta (pink circles). A convoluted set of ER 
tubules occupy an axis between nuclei (*asterisk). Following high levels of CSQ2-
DsRed expression and smooth ER accumulation, smooth ER no longer effectively 
transitions to jSR sites, leading to a changes in ER and SR membrane partitioning (gray 
fill). 
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6.4 Conclusions  
In cardiomyopathies capable of producing HF, some change in the pathway for 
CSQ2 occurs.  It can be detected by changes in CSQ2 processing, and its regulation 
(perhaps by CK2 phosphorylation in rough ER) may regulate a relative transition of ER 
form its contractile role to a more transcriptional and hypertrophic function.  Whether 
mass redistribution corresponds to SR morphological remodeling, or is regulated at the 
level of CSQ2 turnover will be interesting questions for future investigations.  It will be 
important to establish which of the several possible mechanisms underlie the altered 
processing of CSQ2 in the myocardium, as these in vivo data may add significant 
insights into adaptive changes in junctional SR physiology and Ca2+ homeostasis in the 
heart.  
Changes in TRD and JCT accumulation occurring in cardiomyopathies show the 
value of understanding the protein trafficking pathways accompanying the biosynthesis 
of functional SR membranes.  This study demonstrates a novel biosynthetic pathway in 
adult cardiomyocytes.  We show that junctional SR Ca2+-release complex protein 
components arrive at junctional SR proximately following synthesis at juxtanuclear 
rough ER sites.  Disruption of the normal trafficking cycle along with altered cellular 
localization could account, in part, for select cardiomyopathies and changes in Ca2+ 
homeostasis.  
Knowledge of pathways leading to functional ER subcompartmentation will 
provide a basis for identifying new mechanisms by which protein glycosylation and 
phosphorylation, and thus trafficking, lead to changes in functional Ca2+ release sites.  
Future studies should focus on understanding the regulatory mechanisms in cardiac 
membrane trafficking changes that occur in disease states, which may be either 
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adaptive or maladaptive.  
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APPENDIX B 
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APPENDIX C 
Supplemental Data 
 
Figure A-1. Levels of 
endogenous rat CSQ2 and JCT 
proteins at various time points in 
culture. Primary adult rat 
cardiomyocytes were harvested 
after 16, 24, 36 or 48 h (A) 
Amido Black stained 
nitrocellulose membrane of 
protein extracts from cultured 
cardiomyocytes treated with 
Ad.JCT (+) or non-treated (-) run 
on Bis-Tris MIDI gel (10 %) (B) 
Immunoblot of CSQ2rat using 
anti-CSQ2rat (C) Immunoblot of 
JCT detected using anti-JCTrat.  
 
 
 
 
 
 
 
 
 
Figure A-2. Time course of 
delTRDdog accumulation at 
junctional SR sites. Coverslips 
containing cardiomyocytes were 
removed and fixed following 
treatment with Ad.delTRDdog for 
18 and 36 h and remaining cells 
harvested for immunoblotting. 
(A-C) Immunofluorescence 
TRDdog (red) and nuclei (blue) at 
different time points, cells were 
stained with anti-TRDdog. Scale 
bar 10µm.  
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Figure A-3. The effect of nocodazole concentration and duration of treatment. 
Immunofluorescence performed on adult rat cardiomyocytes treated with nocodazole as 
indicated, fixed and stained with anti-JCTdog (red) after 48 h in culture. (A) 
Cardiomyocyte expressing JCTdog and treated with nocodazole for 2 h (B) 
Cardiomyocyte expressing JCTdog and treated with nocodazole for 12 h (C) 
Autoradiograms of immunoblot performed on protein extracts from cardiomyocytes 
treated with Ad.JCT for 48 h either with or without 20 M nocodazole for 36 h showing 
JCTdog and α-tubulin levels.  
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Figure A-4. Junctional SR sites 
distribution depicted by CSQ2rat 
endogenous protein localization upon 
nocodazole treatment. Cultured 
cardiomyocytes co-stained with anti-
CSQ2rat (red) and anti-α-tubulin 
(green). (A) Cardiomyocyte without 
nocodazole treatment (A1) α-tubulin, 
green channel from panel A (A2) red 
channel from panel A showing 
CSQ2rat (B) Cardiomyocyte treated 
in culture with nocodazole (20 M) 
(B1) α-tubulin, green channel from 
panel B (B2) red channel from panel 
B showing CSQ2rat. 
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ABSTRACT	
JUNCTIONAL SARCOPLASMIC RETICULUM PROTEIN PROCESSING AND 
TRAFFICKING IN CARDIAC TISSUE AND PRIMARY CULTURED 
CARDIOMYOCYTES 
by  
NA’AMA H. SLEIMAN 
August 2014 
Advisor: Steven Cala Ph.D. 
Major: Physiology 
Degree: Doctor of Philosophy  
Junctional SR is an important and unique ER subdomain in the adult myocyte 
that releases Ca2+ through the actions of an exclusive set of resident proteins.  Cardiac 
calsequestrin (CSQ2) undergoes two co-translational modifications: N-linked 
glycosylation on 316Asn, and phosphorylation by protein kinase CK2 on a cluster of 3 
serines in its tail.  In the heart, CSQ2 molecules undergo extensive mannose trimming 
by ER mannosidase(s), a posttranslational process that often regulates protein 
breakdown.  To investigate CSQ2 protein processing in cardiomyopathy models, 
studies were performed to test whether CSQ2 glycan structures would be altered in 
heart tissue from mongrel dogs induced into heart failure (HF) by two different 
experimental treatments, rapid ventricular pacing or repeated coronary 
microembolizations. CSQ2 mRNA and protein levels were determined, and its 
processing was analyzed by electrospray mass spectrometry.  Despite the different 
cardiomyopathies producing the failure, roughly one-third of CSQ2 molecules from each 
of the failed tissues contained glycan structures indicating a buildup of newly made 
protein with highly reduced glycan trimming.  Analyses of tissue samples showed 
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decreases in CSQ2 protein levels per unit levels of mRNA for tachypaced heart tissue, 
also indicative of altered turnover.  
To place these data in context of junctional SR cell biology, we carried out a 
series of studies on primary rat cardiomyocytes to understand the basic features of 
junctional SR protein trafficking.  We expressed canine forms of junctin (JCT), triadin 
(TRD) and CSQ2 in adult rat cardiomyocytes, each a major protein component of the 
Ca2+ release complex.  Two additional reagents employed were CSQ2-DsRed, which 
fails to leave sites of early synthesis due to immediate polymerization, and so was able 
to bind TRD and JCT in rough ER; and a deletion mutant of TRD (delTRD) which was 
not so affected, and allowed us to directly probe the differences between ER and SR by 
double labeling.  A complex picture emerged, in which all junctional SR proteins are 
synthesized in the nuclear envelope but travel across MT linked smooth ER to 
continuously deposit junctional SR proteins.  The data suggest that ER proteins traffic 
radially along Z-lines, and axially between nuclei, maintaining junctional SR protein 
levels through sorting and selective retention as ER traverses Z-lines.  ER protein traffic 
requires intact MTs, as nocodazole treatment led to loss of anterograde JCT and TRD 
traffic away from the nuclear envelope.  
We conclude that altered processing of CSQ2 may be an adaptive response to 
the myocardium under stresses that are capable of inducing heart failure.  We provide a 
model of ER and SR protein transport across the cardiomyocytes, and a new 
understanding of pathways by which cellular Ca2+ handling protein complexes can be 
maintained and modified.  
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